Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
AU777221B2 - Heterocycle substituted diphenyl leukotriene antagonists - Google Patents
[go: Go Back, main page]

AU777221B2 - Heterocycle substituted diphenyl leukotriene antagonists - Google Patents

Heterocycle substituted diphenyl leukotriene antagonists Download PDF

Info

Publication number
AU777221B2
AU777221B2 AU17610/01A AU1761001A AU777221B2 AU 777221 B2 AU777221 B2 AU 777221B2 AU 17610/01 A AU17610/01 A AU 17610/01A AU 1761001 A AU1761001 A AU 1761001A AU 777221 B2 AU777221 B2 AU 777221B2
Authority
AU
Australia
Prior art keywords
compound
pgl
group
ethyl
cooh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU17610/01A
Other versions
AU1761001A (en
Inventor
Douglas Wade Beight
William Thomas Mcmillen
Jason Scott Sawyer
Edward C. R. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU1761001A publication Critical patent/AU1761001A/en
Application granted granted Critical
Publication of AU777221B2 publication Critical patent/AU777221B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Description

WO 01/34580 PCT/US00/30942 -1- HETEROCYCLE SUBSTITUTED DIPHENYL LEUKOTRIENE ANTAGONISTS CROSS REFERENCE TO RELATED APPLICATION This case claims the priority benefit of United States Provisional Patent Application Serial No. 60/164,703, filed 1i NovcdiuLji 1333, Llt l Lusui uL wlsilch i ijUULJ.uiLtC herein by reference.
BACKGROUND OF THE INVENTION The metabolic routes in which various compounds are biosynthesized from arachidonic acid, are collectively called the "Arachidonic Acid Cascade." Leukotriene B 4
(LTB
4 is one of many products resulting from the arachidonic acid cascade.
Moreover, LTB 4 in high concentration has been detected at the sites of various inflammaitory conditions, for example, rheumatism, spinal arthritis (see Klickstein L.B., Shapleigh, C. and Goetzl, E. J. (1980) J. Clin. Invest., 66, 1166-1170), gout (Rae, S. Davidson, E. M. and Smith, M.
J. H. (1982) Lancet II 1122-1123), psoriasis (see Grabbe, Czarnetzki, B. Rosenbach, T. and Mardin, M. (1984) J. Invest. Dermatol., 82, 477-479), ulcerative colitis (see Sharon, P. and Stenson, W. F. (1984) Gastroenterology 86, 453-460). and respiratory disease (see O'Driscoll, B. R., Cromwell, 0. and Kay, A. B. (1984) Clin. Exp., Immunol., 397-404). The facts described above show that LTB 4 is deeply related to various forms of inflammation. It has been suggested that compounds antagonizing LTB 4 activity may be valuable in the treatment of inflammatory diseases caused by tissue degrading enzymes and reactive chemicals liberated by tissue-infiltrating and aggregating polymorphonuclear leukocytes.
WO 01/34580 PCT/US00/30942 -2- For example, PCT Japanese National Publication No. 6- 502164 describes novel monocylic or bicyclic aryl compounds are selectively antagonistic to LTB 4 and are useful for treatment of rheumatoid arthritis, gout, psoriasis and inflammatory bowel disease. Japanese Unexamined Patent Publication (Kokai) No. 4-244023 describes that omega 6 series unsaturated fatty acids such as y-linolenic acid are useful for treatment of arrhythmia, acute myocardial infarction etc, by inhibiting production of LTB 4 Japanese Unexamined Patent Publication No. 5-310668 describes that a novel leucine derivative has an inhibitory action to LTA 4 hydrolase and is useful for treatment and prophylaxis of allergic diseases such as bronchial asthma, various inflammatory diseases, and ischemia-reperfusion disorders.
Japanese Unexamined Patent Publication (Kokai) No. 1-190656 discloses that novel leukotriene B 3 dimethyl amide has an antagonistic action to LTB 4 and is useful as antiinflammatory drug, anti-rheumatic drug and gout-treatment drug.
The article, "Second Generation Leukotriene B 4 Receptor Antagonists Related to SC-41930: Heterocyclic Replacement of the Methyl Ketone Pharmacophore", J. Med Chem, 1995, 38, p.858-868 by Penning, Thomas D. et. al.; describes heterocycle substituted LTB 4 antagonists.
Pyrazole LTB 4 antagonists are disclosed in the article, "Leukotriene B 4
(LTB
4 Receptor Antagonists: A Series of (Hydroxyphenyl)pyrazoles" by Richard W. Harper, et. al., J.
Med Chem, 1994, 37, pgs. 2411-2420.
Leukotriene B 4 antagonists, inclusive of diphenyl ethers such as 2-[2-propyl-3-[3-[2-ethyl-5-hydroxy-4-(4fluorophenyl)phenoxy]propoxy]phenoxy]benzoic acid, are described in United States Patent No. 5,462,954, the disclosure of which is incorporated herein by reference.
The same type of leukotriene B 4 antagonists are described in WO 01/34580 PCT/US00/30942 -3the article, "Synthetic and Structure/Activity Studies on Acid-Substituted 2-Arylphenols: Discovery of 2-[2-Propyl-3- [3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]phenoxy]benzoic Acid, a High-Affinity Leukotriene B 4 Receptor Antagonist" by J. Scott Sawyer, et. al., Journal of Medicinal Chemistry, 1995, 38, pgs. 4411-4432.
These diphenyl ether leukotriene B 4 antagonists, in combination with a 2',2'-difluoronucleoside analog GEMCITABINE HC1) have also been found to have utility in the treatment of various cancers, as further described in Provisional Patent Application Serial Number 60/164786, filed 11 November 1999, the disclosure of which is incorporated herein by reference.
Currently, anti-inflammatory drugs are classified as steroidal and non-steroidal. Although these drugs provide anti-inflammatory action they all have drawbacks which limit their use. A more recent approach to the moderation of inflammation focuses on blocking the action of arachidonic acid metabolites.
Leukotriene B 4 antagonists are useful for a wide variety of Inflammatory Diseases, but it is expected that various of these antagonists will show superior results with particular disease states. This is one reason it is desirable to develop new leukotriene B 4 antagonists such as the compounds of this invention.
SUMMARY OF THE INVENTION The present invention is directed to novel heterocycle substituted diphenyl compounds of formula (I) 4
OH
'R 3 (CH2)n Y 2
R
1
Y
z
(I)
Another aspect of this invention is a pharmaceutical compositions which comprises a therapeutically effective amount of a compound of the invention and a pharmaceutically a3 C ptCIuI C dillliCi UI UlIIvIIL.
Another aspect of this invention is a method for the treatment or prevention of Inflammatory Diseases, which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of the invention.
Another aspect of this invention is a method for in vivo inhibition of leukotriene B 4 in a mammal in need thereof, which comprises administering to said mammal a therapeutically effective amount of a compound of the invention.
Another aspect of this invention is a compound of the invention for use as a medicament in the treatment or prevention of Inflammatory Diseases.
Another aspect of this invention is a compound of the invention for use as a medicament in the in vivo inhibition of leukotriene B 4 in a mammal in need thereof.
Another aspect of this invention is a compound of formula I of the invention when used to treat or prevent inflammatory diseases.
Another aspect of this invention is a compound of formula I of the invention when used in the in vivo inhibition of leukotriene B 4 in a mammal in need thereof.
Another aspect of this invention is a pharmaceutical composition of the invention when used to treat or prevent inflammatory diseases.
Another aspect of this invention is a pharmaceutical composition of the invention when used in the in vivo inhibition of leukotriene B 4 in a mammal in need thereof.
Another aspect of this invention is use of a compound of formula I of the invention 25 in the manufacture of a medicament to treat or prevent inflammatory disease.
0* 1 Another aspect of this invention is use of a compound of formula I of the invention *for the manufacture of a medicament for thc in vivo inhibition of leukotriene B 4 in mammal.
[R:\LIBVV103480spci.doc:njc 4a Detailed Description I. Definitions: The term, "Acidic Group" means an organic group which when attached as the "Z" substituent of formula or the "Z2" substituent of formula (II) acts as a proton donor capable of hydrogen bonding. An illustrative acidic group is carboxyl.
The term, "Active Ingredient" means the diphenyl leukotriene B 4 antagonist compounds generically described by formula I and formula II or the list of specific diphenyl compounds disclosed, infra., as well as the salts, solvates, and prodrugs of such compounds.
The term, "alkenyl" means a monovalent radical of the generic formula CnH 2 n such as ethenyl, n-propenyl, isopropeneyl, n-butenyl, isobutenyl, 2-butenyl, and
S*
BVV03480speci.doc:njc WO 01/34580 PCT/US00/30942 3-butenyl.
The term, "alkyl" by itself or as part of another substituent means, unless otherwise defined, a straight or branched chain monovalent hydrocarbon radical such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tertiary butyl, sec-butyl, n-pentyl, and n-hexyl.
The term, "alkaryl" means an aryl radical substituted with an alkyl or substituted aryl group, for example:
C
3
H
8 In the term, "C 6
-C
2 0 alkaryl" the numerical subscripts refer to the total number of carbon atoms in the radical.
The term, "C 6
-C
2 0 aralkyl" means an alkyl radical substituted with an aryl or substituted aryl group, for example: In the term, "C 6
-C
20 aralkyl" the numerical subscripts refer to the total number of carbon atoms in the radical.
The term, "carbocyclic group" refers to a five, six, seven, or eight membered saturated, unsaturated or aromatic ring containing only carbon and hydrogen benzene, cyclohexene, cyclohexane, cyclopentane).
WO 01/34580 PCT/US00/30942 -6- The term, "cycloalkyl" means a carbocyclic nonaromatic monovalent radical such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
The term, "halo" means fluoro, chloro, bromo, or iodo.
The term, "heterocyclic radical(s)" refers to a radical having a saturated, unsaturated or aromatic five membered substituted or unsubstituted ring containing from 1 to 4 hetero atoms.
The term, "Inflammatory Diseases" refers to diseases such as inflammatory bowel disease, sepsis, septic shock, adult respiratory distress syndrome, pancreatitis, traumainduced shock, bronchial asthma, allergic rhinitis, rheumatoid arthritis, cystic fibrosis, stroke, acute bronchitis, chronic bronchitis, acute bronchiolitis, chronic bronchiolitis, osteoarthritis, gout, spondylarthropathris, ankylosing spondylitis, Reiter's syndrome, psoriatic arthropathy, enterapathric spondylitis, Juvenile arthropathy or juvenile ankylosing spondylitis, reactive arthropathy, infectious or post-infectious arthritis, gonoccocal arthritis, tuberculous arthritis, viral arthritis, fungal arthritis, syphilitic arthritis, Lyme disease, arthritis associated with "vasculitic syndromes", polyarteritis nodosa, hypersensitivity vasculitis, Luegenec's granulomatosis, polymyalgin rheumatica, joint cell arteritis, calcium crystal deposition arthropathris, pseudo gout, non-articular rheumatism, bursitis, tenosynomitis, epicondylitis (tennis elbow), carpal tunnel syndrome, repetitive use injury (typing), miscellaneous forms of arthritis, neuropathic joint disease (charco and joint), hemarthrosis (hemarthrosic), Henoch-Schonlein Purpura, hypertrophic osteoarthropathy, multicentric reticulohistiocytosis, arthritis associated with certain diseases, surcoilosis, hemochromatosis, sickle cell disease WO 01/34580 PCT/US00/30942 -7and other hemoglobinopathries, hyperlipoproteineimia, hypogammaglobulinemia, hyperparathyroidism, acromegaly, familial Mediterranean fever, Behat's Disease, systemic lupus erythrematosis, or relapsing polychondritis and related diseases which comprises administering to a mammal in need of such treatment a therapeutically effective amount of the compound of formula I in an amount sufficient to act as an antagonist for leukotriene B 4 and its deleterious products.
The term, "LTB 4 antagonist" means a pharmaceutical agent capable of preventing or reducing to a therapeutically significant degree the adverse activity of LTB 4 in mammals and having a average CDllb/CD18 ICo 0 (nM) assay result of 10000 or less and preferably of 100 or less.
The term, "mammal" includes human.
The term, "N-sulfonamidyl" means the radical: 11 H 0 0 where R12 is C 1
-C
1 0 alkyl, aryl, C1-C6 alkyl substituted aryl, C 6
-C
20 alkaryl, or C 6
-C
20 aralkyl.
The term, "substituted alkyl" means an alkyl group further substituted with one or more radical(s) selected from halo, C 1
-C
6 alkyl, aryl, benzyl, C 2
-C
6 alkenyl, C 2
-C
6 alkynyl, C 3
-C
8 cycloalkyl, C 1
-C
8 alkoxy, C 1 -Cg haloalkyl
-CF
3 The term, "substituted aryl" means an aryl group further substituted with one or more radical(s) selected from halo, C 1
-C
6 alkyl, aryl, benzyl, C 2
-C
6 alkenyl, C 2
-C
6 alkynyl, C 3 -Cg cycloalkyl, C 1 -Cg alkoxy, C 1
-C
6 haloalkyl
-CF
3 WO 01/34580 PCT/USOO/30942 -8- The term, "tetrazolyl" refers to an acidic group represented by either of the formulae: N N HN-N I I or I I N' NH N- N II. Compounds of the Invention: The present invention is directed to novel heterocyclic substituted diphenyl compounds of formula (I)
H
R3 Y H2 2 1 R4 R1
(I)
wherein: X is selected from the group consisting of, a five membered substituted or unsubstituted heterocyclic radical containing from 1 to 4 hetero atoms independently selected from sulfur, nitrogen or oxygen; or (ii) a fused bicyclic radical wherein a carbocyclic group is fused to two adjacent carbon atoms of the five membered heterocyclic radical,
Y
1 is a bond or divalent linking group containing 1 to 9 atoms; WO 01/34580 WO 0134580PCTIUSOO/30942 -9-
Y
2 and Y 3 are divalent linking groups independently selected from -CH 2 and Z is an Acidic Group; RI is C 1 -Cl 0 alkyl, aryl, C 3 -Cl 0 cycloalkyl,
C
2 -Cl 0 alkenyl, C 2
-C
10 alkynyl, C 6
-C
20 aralkyl, C 6
-C
20 alkaryl, C 1
-C
10 haloalkyl, C 6
-C
20 aryloxy, or Cl-Cl 0 alkoxy; R2 is hydrogen, halogen, Cl-Cl 0 haloalkyl, C 1
-C
10 alkoxy,
C
1
-C
10 alkyl, C 3
-C
8 cycloalkyl, Acidic Group, or
(CH
2 1-7 (Acidic Group); R3 is hydrogen, halogen, Cl-Cl 0 alkyl, aryl, Cl-C 10 haloalkyl, Cl-C 10 alkoxy, C 1
-C
10 aryloxy, C 3
-C
8 cycloalkyl; R4 is Cl-C 4 alkyl, C 3
-C
4 cycloalkyl,
-(CH
2 1 7 cycloalkyl), C 2
-C
4 alkenyl, C 2
-C
4 alkynyl, benzyl, or aryl; and n is 0, 1, 2, 3, 4, 5, or 6; or a pharmaceutically acceptable salt, solvate, or prodrug derivative thereof.
III. Preferred Compounds of the Invention: III A. Preferred X substituents: A "substituted heterocyclic radical" is preferably Substitued with from 1 to 3 groups independently selected from hydrogen, halo, Cl-C 10 alkyl, C 1
-C
10 haloalkyl, Cl-Cl 0 alkoxy, aryl, or C 6
-C
20 aryloxy.
WO 01/34580 WO 0134580PCTIUS00/30942 Preferred Group 1 of X substitueit (symbol, "PGl-X') Preferred compounds of the invention are those wherein X is a heterocyclic radical selected from the group consisting of substituents represented by the following structural formulae: 7 R11 R1 R11 /N R11 0 11 %'SI'lN -N R11
S
N
I
~7R1 1
N
0
N
N z RiO
N-N
Y R1 1 N-N RI
F
7 4 R1 1
N-N
_0zN WO 01/34580 PCT/US00/30942 -11- 11N R1R11 R11 NN N S 0 S IN N N N N11 0 S .N
H
N- R 1 1 T sand N R11 where R10 is a radical selected from hydrogen or
C
1
-C
4 alkyl; and R11 is a radical selected from hydrogen, halo, C 1
-C
10 alkyl, C 1
-C
10 haloalkyl, C 1
-C
10 alkoxy, aryl, or C 6
-C
20 aryloxy. Preferred R10 groups are hydrogen, methyl, or phenyl. Moreover, any of the above heterocyclic radicals illustrated by structural formulae may attach to the diphenyl leukotriene antagonist of formulae by any monovalent bond originating on a suitable carbon or nitrogen atom in its ring structure.
For example, the pyrrole radical may attach to the diphenyl molecule by a single bond originating at any carbon WO 01/34580 PCT/US0O/30942 -12atom or any nitrogen atom which has less than three bonds in the hererocyclic ring; Location of attachment bond for pyrrole,
N
H
N
H
N
A preferred form of t bicyclic radical wherein a adjacent carbon atoms of t radical, for example:
H
N
he substituent X is a fused carbocyclic group is fused to two he five membered heterocyclic
N
H
and III B. Preferred Group 2 of X substituent (symbol, "PG2- Most preferred as the X substituents are the heterocyclic radicals; CHg- N
S
0O or WO 01/34580 PCT/US00/30942 -13- III C. Excluded X substituents: The heterocyclic radical X of Formula does not include 3-bromo-1,2,4 thiadiazole since the LTB 4 antagonist activity of compounds containing this radical is considered too low to be an aspect of this invention.
III D.
Y1 9 atoms sulfur, Preferred Y 1 substituents: is a bond or divalent linking group containing 1 to independently selected from carbon, hydrogen, nitrogen, and oxygen; Preferred Group 1 of Yi substituent (symbol, "PG1-Yi") Preferred compounds of the invention are those wherein
Y
1 is a divalent linking group selected from the group consisting of substituents represented by the following formulae: WO 01/34580 WO 01/34580 CTUSSO//009 2 -14- -0
C-
H
2
-N
R13
-S
0
-C
o -C
H
2
H
2 -0---HC
H
2 nj
C
H
2 R13C I H2 fI -c I H2 0 where R13 is hydrogen, methyl, or ethyl; WO 01/34580 PCT/US00/30942 The above divalent groups may be used in their forward or reversed positions. For example, the group;
H,
may be positioned as either, R2 R3 R3 R1 O or R1 0 in the displayed fragment of formula III E. Preferred Group 2 of Yi substituent (symbol, "PG2-
Y
1 The most preferred divalent Y 1 substituent is the group; 0 III F. Preferred Group 1 of Y 2 substituent (symbol, "PG1-
Y
2 and Preferred Group 1 of Y 3 substituent (symbol, "PG1- Y3") The Y 2 and Y 3 substituents are preferably selected from and III G. Preferred Group 2 of Y 2 substituent (symbol, "PG2- Y2") and Preferred Group 2 of Y 3 substituent (symbol, "PG2-
Y
3 WO 01/34580 WO 0134580PCTIUSOO/30942 -16- Most preferably both Y 2 and Y 3 are the group; -0 111 H. Preferred Group 1 of Z substituent Z LILI GL.LIJ± 131 Lpd pLev.Luu51y Lteft~rLed is an acidic group selected from the following: C-NS 1 2 II
H
0 0 tetrazolyl, -SO3H,
OH-O
-O
OH
WO 01/34580 WO 0134580PCTIUSOO/30942 -17- 0 J OH or where R12 is C 1
-C
1 0 alkyl, aryl, C 6
-C
2 0 alkaryl, or C-2 aralkyl. Preferred R12 groups are represented by the formulae:
CH
3 111 1. Preferred Group 2 of Z substituent (symbol, "PG2-Z"): Highly preferred are the acidic groups; tetrazolyl, N-acyl sulfonamide, -S03H, and carboxyl.
III J. Preferred Group 3 of Z substituent (symbol, 'PG3-Z"): Carboxyl is the most preferred Z substituent.
111 K. Preferred Group 1 of n subscript variable (symbol, "PG1-n") The most preferred integer values for the divalent linking group, -(CH2)n- are n=1, n=2, and n=3.
WO 01/34580 PCT/US00/30942 -18- III L. Preferred Group 2 of n subscript variable (symbol, "PG2-n") The most preferred integer value of n for the divalent linking group, -(CH2)n- is n 1.
III M. Preferred Group 1 of R1 substituent (symbol, "PG1- R1.": A preferred R1 group is methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, and 2-propenyl; with npropyl being most preferred.
III N. Preferred Group 1 of R2 substituent (symbol, "PG1-R2")and Preferred Group 1 of R3 substituent (symbol, "PG1-R3"): Preferred R2 and R3 groups are those wherein R2 and R3 are independently selected from hydrogen or methyl, ethyl, methoxy, ethoxy, halo, or -CF3; with R2 and R3 both being hydrogen as most preferred.
III 0. Preferred Group 1 of R4 substituent (symbol, "PG1-R4":) Preferred R4 substituents are ethyl, propyl, and isopropyl.
III P. Combinations of substituents of the compound of Formula The substituents of formula are defined as and "Y3".
Moreover, as described in the preceding section, within each of the defined substituents of Formula are "preferred" and "most preferred" subgroups which define the variety of substituents to be used in the definition of LTB 4 antagonists of the invention. These preferred subgroups are defined by designations such as "PG1-R4" as WO 01/34580 WO 0134580PCT[USOOI30942 -19recited above. it is often advantageous to use combinations of preferred groups or combinations of preferred groups together with the general definition of variables given in Formula Suitable combinations of substituents are shown in the following three Tables (viz., R-Table, Y-Table XZn-Table).
of general and preferred groupings of the variables Rl, R2, R3 and R4 for substitution in formula as follows: R-Table R variables Rl R2 R3 R4 Combination group group group group Code choice' choice choice choice R01 R1 R2 R3 R4 R02 Rl* R2 R3 PGl-R4 10103' RI- PI-3 n R04 R1 R2 PGl-R3 PG1-R4 Rl PGl-R2 R3 R4 R06 R1 PGl-R2 R3 PG1-R4 R07 Rl PGl-R2 PGl-R3 R4 ROB R1 PGl-R2 PGl-R3 PGl-R4 R09 PGl-Rl R2 R3 R4 PGl-Q1 R2 R3 PGl-R4 R11 PG1-Rl R2 PGl-R3 R4 R12 PGl-R1 R2 PGl-R3 PG1-R4 R13 PGl-Rl PGl-R2 R3 R4 R14 P01-Ri PGl-R2 R3 PGl-R4 P01-Ri PGl-R2 PG1-R3 R4 R16 P01-Ri PGl-R2 IPGl-R3 PGl-R4 Thus, for example, the substituent combination, 'IR14
M
describes a substituent combinatorial choice for Formula wherein Rl is selected from the preferred set of WO 01/34580 PCT/US00/30942 variables, "PG1-R1", that is, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, and 2-propenyl; the R2 substituent is selected from the preferred set of variables, "PG1-R2", that is, hydrogen or methyl, ethyl, methoxy, ethoxy, halo, or -CF 3 the variable R3 has the scope defined in the generic formula and the substituiints s11itahl. for R4 ar slP R1-prI-C from t-h preferred group, "PG1-R4" having the preferred set of variables, ethyl, propyl, and isopropyl.
The following Y-Table is used to select broad and preferred groupings of the variables Y1, Y2, and Y3 for substitution in formula as follows: wo 01/34580 WO 0134580PCTJUSOO/30942 -21- Y-Table Y variables -Y1 group Y2 group Y3 group combination choice choice choice code YO1 Y1 Y2 Y3 vrv) V1 VcIi or,1-VI Y03 Y1 Y2 PG2-Y3 Y04 Yl PGl-Y2 Y3 Yl PG2-Y2 Y3 Y06 Yl PGl-Y2 PG1-Y3 Y07 Yl PGl-Y2 PG2-Y3 Y08 Yl PG2-Y2 PG1-Y3 Y09 Yl PG2-Y2 PG2-Y3 PG1-YI Y2 Y3 Y1l PG1-Y1 Y2 PG1-Y3 PGiL XL PG2L13 Y13 PG1-Y1 PG1-Y2 Y3 Y14 PG1-Yl- PGl-Y2 PG1-Y3 PGl-Y1 PGl-Y2 PG2-Y3 Y16 PGl-Yl PG2-Y2 Y3 Y17 PG1-Yl PG2-Y2 PG1-Y3 Y1B PGl-Yl PG2-Y2 PG2-Y3 Y19 PG2-Y1 Y2 Y3 PG2-Y1 Y2 PG1-Y3 Y21 PG2-Y1 Y2 PG2-Y3 Y22 PG2-Y1 PGl-Y2 Y3 Y23 PG2-Yl PG1-Y2 PG1-Y3 Y24 PG2-Y1 PGl-Y2 PG2-Y3 PG2-Yl PG2-Y2 Y3 Y26 PG2-Y1 PG2-Y2 PGl-Y3 Y27 PG2.-YI. PG2-Y2 PG2-Y3 WO 01/34580 WO 0134580PCTJUSOO/30942 -22- The following XZn-Table is used to select broad and preferred groupings of the variables X, Z, and n for substitution in formula as follows: XZn-Table combination group Group group code choice Choice choice XZnOl X Z n XZnO2 X Z PGl-n xZnO3 X Z PG2-n XZnO4 X PG1-Z n X PG2-Z n XznO6 X PG3-Z n XZnO7 X PG1-Z PGl-n XZnO8- X lu -G/I2 Pul-n XZnO9 X PG3-Z P01-n XZnlO X PGl-Z PG2-n XZnll X PG2-Z PG2-n XZn12 X PG3-Z P02-n XZn13 PGl-X Z n XZnl4 PGl-X Z PGl-n PGl-X Z P02-n XZnl6 PG1-X PG1-Z n XZnl7 PG1-X PG2-Z n XZnl8 PG1-X PG3-Z n XZn19 PG2-X PG1-Z PGl-n XZn2O PG2-X PG2-Z P01-n XZn2l PG2-X PG3-Z PG1-n XZn22 PG2-X PGl-Z P02-n Y~2 7.1' 4 v' G-Z P0- XZn24 PG2-X jPG3- Z PG2-n WO 01/34580 PCT/US00/30942 -23- How to Use the Tables: Any of the individual 16 combinations of the R substituents depicted in the R-Table may be used in combination with any of the 27 individual combinations of Y substituents depicted in the Y-Table, which may be used uri t-h An- r-%f t-li=, e-r'rmnirin i ncz rrf Y7.n ciic-i +-iIn nf a depicted in the XZn-Table. For example, the substituent combination choice "R07, Y21, XZn03" defines substituent set selections for a subset of formula useful in the practice of the invention.
III Q. Preferred compounds of the invention are described by formula (II): X2 I R21
(II)
wherein; X2 is a heterocyclic radical selected from, H- N S
CH
3 N 0 or WO 01/34580 WO 0134580PCTUSOO/30942 -24- R21 is ethyl, 2-propen-1-yl, 3-propen-1-yl, n-propyl, iso-propyl, n-butyl, sec-butyl, or tert-butyl; and R22 is hydrogen, n-butyl, sec-butyl, flouro, chioro,
-CF
3 or tert-butyl.
Z2 is carboxyl, tetrazolyl,' N-sulfonamidyl.
Preferred Compounds of the Invention: 111 R. Specific compounds preferred as LTB 4 antagonists are represented by the following structural formulae: (Cl) ,N H 07
COOH
(C2):
HC
4N OH
COOH
(C3): WO 01/34580 WO 0134580PCTIUSOO/30942
COO
COOH
(rd i (C6): ,N OH
N.
N' COOH (C7) WO 01/34580 WO 0134580PCT/USOO/30942 -26-
O",N,
(C8)
I
COOH
(ClO) WO 01/34580 WO 0134580PCT[USOOI30942 -27- (Cll) (C12):
COOH
(C13):
ITP
COOH
(C14) COONa WO 01/34580 WO 0134580PCTUSOI3942 -28-
*HCI
(C16): (C17): (C18) (C19) WO 01/34580 WO 01/.4580PCTIUSOO/30942 -29- (C21): (C22):
COCH
(C2 3): WO 01/34580 WO 0134580PCTUSOOI30942
OH
S
COOH
and all acid, salt, solvate and prodrug derivatives thereof.
III S. Highly Preferred Compounds of the Invention are as follows: S OH
COOH
0 OH COONa WO 01/34580 PCT/US00/30942 -31- _4 OH
COOH
SOH
o N J COOH
OH
N
0 o N0
COOH
and all acid, salt, solvate and prodrug derivatives thereof.
The salts of the above diphenyl LTB 4 antagonists of the invention, represented by formulae and (II) and the specific compounds set out by structural formulae in sections IIIR and IIIS herein, are an additional aspect of the invention. The compounds of the invention possess an Acidic Group(s) and at these sites various salts may be formed which are more water soluble and/or physiologically suitable than the parent compound in its acid form.
Representative pharmaceutically acceptable salts, include but are not limited to, the alkali and alkaline earth salts f such as !ithi si, pots-S= iw aI' rcalcy, esi, aluminum and the like. Sodium salts are particularly WO 01/34580 PCTUSOO/30942 -32preferred. Salts are conveniently prepared from the free acid by treating the acid form in solution with a base or by exposing the acid to an ion exchange resin. For example, the (Acidic Group) of the Z of Formula may be selected as -C0 2 H and salts may be formed by reaction with appropriate bases NaOH, KOH) to yield the Included within the definition of pharmaceutically acceptable salts are the relatively non-toxic, inorganic and organic base addition salts of compounds of the present invention, for example, ammonium, quaternary ammonium, and amine cations, derived from nitrogenous bases of sufficient basicity to form salts with the LTB 4 antagonist compounds of this invention (see, for example, S. M. Berge, et al., "Pharmaceutical Salts," J. Phar. Sci., 66: 1-19 (1977)).
Cr~n comnpounds of the ilnvetn my more chiral centers and may thus exist in optically active forms. All such stereoisomers as well as the mixtures thereof are intended to be included in the invention. If a particular stereoisomer is desired, it can be prepared by methods well known in the art, for example, by using stereospecific reactions with starting materials which contain the asymmetric centers and are already resolved or, alternatively, by methods which lead to mixtures of the stereoisomers and subsequent resolution by known methods.
For example, a racemic mixture may be reacted with a single enantiomer of some other compound. This changes the racemic form into a mixture of diastereomers. Then, because the diastereomers have different melting points, different boiling points, and different solubilities, they can be separated by conventional means, such as crystallization.
Prodrugs are derivatives of the compounds of Formula and supra., which have chemically or metabolically WO 01/34580 PCT/USOO/30942 -33cleavable groups and become by solvolysis or under physiological conditions the compounds of the invention which are pharmaceutically active in vivo. Derivatives of the compounds of this invention have activity in both their acid and base derivative forms, but the acid derivative form often offers advantages of solubility, tissue compatibility, or delayed release in a mammalian orqanism (see, Bundcard, Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985). Prodrugs include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acidic compound with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a suitable amine. Simple aliphatic or aromatic esters derived from acidic groups pendent on the compounds of this invention are preferred prodrugs. In some cases it is desirable to prepare double ester type prodrugs such as (acyloxy) alkyl esters or ((alkoxycarbonyl)oxy)alkyl esters. Particularly preferred esters as prodrugs are methyl, ethyl, propyl, isopropyl, nbutyl, isobutyl, tert-butyl, morpholinoethyl, and N,Ndiethylglycolamido.
Esters of carboxylic acids are preferred prodrugs of the compounds of the invention (viz., the compounds of Formula I, Formula II and the specific compounds set out in Section IIIR and IIIS, herein).
Methyl ester prodrugs may be prepared by reaction of the acid form of a compound of formula in a medium such as methanol with an acid or base esterification catalyst NaOH, H 2
SO
4 Ethyl ester prodrugs are prepared in similar fashion using ethanol in place of methanol.
N,N-diethylglycolamido ester prodrugs may be prepared by reaction of the sodium salt of a compound of Formula (I) (in a medium such as dimeLhylforiide) wiLh 2-chloro-N,N- WO 01/34580 PCT/US00/30942 -34diethylacetamide (available from Aldrich Chemical Co., Milwaukee, Wisconsin USA; Item No. 25,099-6).
Morpholinylethyl ester prodrugs may be prepared by reaction of the sodium salt of a compound of Formula (in a medium such as dimethylformamide) 4-(2chloroethyl)morpholine hydrochloride (available from Aldrich Chemicra C~n Milwanik. Wironni n TIA.- Tt-.m No. C4.220-3 Preferred compounds of the invention are compounds of Formula or Formula (II) or the specific compounds of sections IIIR and IIIS shown above by structural formula; wherein the acid, salt and prodrug derivatives thereof are respectively selected from: carboxylic acid, sodium salt, and ester prodrug.
IV. Method of Making the Compounds of the Invention General reaction schemes (not represented to be specific Examples) applicable for synthesis of the LTB4 antagonist compounds represented by formula are set out below. Numerous literature references and Chemical Abstract registry numbers RN 152609-60-4) are supplied as additional aids for preparing reagents used in practicing the synthesis schemes of the invention.
REACTION SCHEMES FOR MAKING THE COMPOUNDS OF THE INVENTION The following scheme illustrates a process for making Example a 4-substituted oxazole LTB 4 receptor antagonist: WO 01/34580 PCT[USOO/30942 Scheme 1 benzyl bromide, Cs 2
CO
3
DMF
knnwn mm FNc 15 5 :-7 R. W. Harper et al., J. Mod. Chem. 1994, 37(15), 2411 HO 0-oY~ 0 JCOOMe known compound: RN 152609.76-2 J. S. Sawyer et al., J. Med. Chem. 1995. 38 4411 (28) K 2 CO. Nal, 2-butanone 0 0
CF
M-Y, 0 'CF, COOMe TFA H 2 0, CH 3
CN
(32) HO 0 H' N1) Tf 2 O, 2,6-jutidine 0 0""o 0-9 2) formamide COOMe (34) 0 a"z:1- 1 BFEtO. EtSH WO 01/34580 PCT/US00/30942 -36i N H 1) NaOH 0 O 0 2) HCI COOMe (38) N H
COOH
(1) Known chloride (26) may be alkylated with benzyl bromide to provide chloride Reaction with known ester catalyzed by a suitable base, provides acetophenone (32).
Oxidation with bis(trifluoroacetoxy)iodobenzene gives alphahydroxy ketone that may be cyclized with triflic anhydride and formamide to give the 4-substituted oxazole Debenzylation with boron trifluoride etherate and ethanethiol gives oxazole that is hydrolyzed and protonated to provide Example Scheme 2 The following scheme illustrates a process for making Example a 5(4)-substituted imidazole LTB 4 receptor antagonist: WO 01/34580 WO 0134580PCTIUSOO/30942 -37- Scheme 2 COOMe 1) LIHMDS, TMSOI. THF 2) NCS 3) TBAF
NH
H
2 N ',SBn
K
2 C0 3 Nal, DMF 6F 3 -Et 2 O, EtSH COOMe 1) UOH, MOCH 2) Raney Ni, EtOH, NaOH 3) HCI
COOH
The trimethylsilyl enol ether of acetophenone (32) is formed and treated with N-chlorosuccinimide followed by tetra-nbutylammonium. fluoride to provide the chloroketone Treatment of (40) with 2-benzyl-2-thiopseudourea and base provides imidazole that is treated with boron WO 01/34580 PCTUS00/30942 -38trifluoride etherate and ethanethiol to give imidazole (44).
Hydrolysis and protonation provide Example as the hydrochloride salt.
Scheme 3 The following scheme illustrates a process for making Example a 4-substituted thiazole LTB recnmptor antagrnnict- WO 01/34580 WO 0134580PCTUSOO/30942 -39- Scheme 3 Lor COOMe COOMe Nthoomamide, MgCO 3 dioxane
BF
3 *Et 2 O. EtSH 1) UOH, MeOH 2) HOI Chioroketone (40) is treated with thioformamide and magnesium carbonate to give thiazole that is debenzylated with boron trifluoride etherate and ethanethiol giving thiazole Hydrolysis and protonation provides Example WO 01/34580 PCT/US00/30942 Scheme 4 The following scheme illustrates a process for making Example a 5(3)-substituted pyrazole LTB 4 receptor antagonist: WO 01/34580 WO 0134580PCTUSOO/30942 -41- Scheme 4 OMe Me 2
N-(
OMe
DMF
1) UOH, MeOH 2) HOI 3) NH 2
NH
2
H
2 0, MeOH BF,-EtO, EtSH N-N* OH o~~o N COOH (4) Treatment of acetophenone (32) with N,N-dimethylfornamide dimethyl acetal gives enone that may be hydrolyzed, PrOtonated, and th.-en heated with hydrazine hydrate to provide pyrazole Debenzylation of the resulting WO 01/34580 PCT/US00/30942 -42pyrazole with boron trifluoride etherate and ethanethiol gives Example Scheme The following scheme illustrates a process for making Example a 5-substituted isoxazole LTB 4 receptor antagonist: WO 01/34580 WO 0134580PCTIUSOO/30942 -43- Scheme Me 2
N
2 ~CO0Me
NH
2 OH, MeOH, H 2 0
BF
3 -Et 2 O, EtSH COOMe (54) COOMe 1) UOH, MeOH 2) HCI (56)
N-
0
OH
COOH
Treatment of enone (50) with hydroxylamine provides isoxazole that is debenzylated with boron trifluoride WO 01/34580 PCT/US00/30942 -44etherate and ethanethiol to give isoxazole Hydrolysis and protonation provides Example Scheme 6 The following scheme illustrates a process for making Example a 5(4)-substituted 1,2,3-triazole LTB 4 receptor antagonist: WO 01/34580 WO 0134580PCTIUSOO/30942 Scheme 6 (58) knowni compounds: RN 152609460-4 J. S. Sawyer et aJ. J. Mod. Chem. 1995, 38, 4411 152609-76-2 K2C03- DMS0 Ae 2-butanone -Sn~tu 3 Pd(PPh) 4
DMF
H
-~COOMO
(64)
TMSN
3 toluene
BF
3 -Et 2 O. EtSH 1) UOH, MeOH 2) HICI
COOH
Known phenol (30) is alkylated with known chloride (58) to give aryl bromide Treatment of (60) with tni-nbutylethynyltin and a palladium catalyst gives al-kye (62)1 Heating (62) with trimethylsilyl azide provides triazole WO 01/34580 PCT/US00/30942 -46that is debenzylated with boron trifluoride etherate and ethanethiol to give triazole Hydrolysis and protonation provides Example Scheme 7 The following scheme illustrates a process for making Example a 1-substituted Dvrrole LTB. receotor antaaonist: WO 01/34580 WO 0134580PCTIUSOO/30942 -47- Scheme 7 1) (KS03)NO, KP0 4
H
2 0 2) 3-pyrroline, CH 3
CN
3) BnBr, K 2 00 3
DMF
OH
OH
1 -bromo-3-chloropropane
K
2 C0 3
DMF
1) Nal, 2-butanane 2) K 2 C0 3
DMF
BF
3 Et 2 O, EtSt-i References for formation of I-aryl substituled pyrrales: M. Mure and J. P. KlInman, J. Am. Chem. Soc. 1995, 117(34), 8698; Y. Lee et J. Am. Chemn. Soc. 1996, 1 18(30), 7241 4-Ethylbenzene-l,3-diol (68) is treated with potassium nitrosodisulfonate followed by 3-pyrroline and benzylbromide WO 01/34580 PCT/US00/30942 -48and a base to provide pyrrole Alkylation with 1bromo-3-chloropropane gives chloride that is used to alkylate phenol (30) to give pyrrole Debenzylation with boron trifluoride etherate and ethanethiol provides Example Scheme 8 The following scheme illustrates a process for making Example a 5-substituted 1,2,4-thiadiazole LTB 4 receptor antagonist: WO 01/34580 WO 0134580PCTIUSOO/30942 -49- Scheme 8
H
00 PdCI 2 ,(dppi) Br
CI
PdCI 2 (dppt), CS 2 C0 3 toluene (76) COOMe 1) BF, 3 Et 2 O, EtSH 2) aq. NaOH 3) aq. HCI (78) The palladium-catalyzed addition of 4,4,5,5-tetranethyl- [l,3,2Jdioxaborolane to bromide (60) gives boronic ester The palladium-catalyzed addition of 1,2,4-thiadiazole to (76) gives ester Debenzylation WO 01/34580 WO 0134580PCTIUSOO/30942 with boron trifluoride etherate and ethanethiol, followed by hydrolysis and protonation, gives Example Scheme 9 The following scheme illustrates a process for making Example a 2-substituted thiophene ILTB 4 receptor antagonist: Scheme 9 (76) 1)S Br PdCI 2 (dppf), CS 2
CO
3 1 toluenea 2) BF 3 -Et 2 O. EtSH 1) aq. LJOH 2) NaCH COONa WO 01/34580 PCT/US00/30942 -51- The palladium-catalyzed addition of boronic ester (76) to 2bromothiophene, followed by debenzylation with boron trifluoride etherate and ethanethiol, provides thiophene Hydrolysis and salt formation provides Example Scheme The tollowing scheme illustrates a process for making Example a 4-substituted pyrazole LTB 4 receptor antagonist: WO 01/34580 WO 0134580PCT/USOO/30942 -52- Scheme
N-N
PdCI 2 (dppf), CS 2
CO
3 toluene (76) 1) BF 3
*EI
2 O, EtSH 2) aq. NaOH 3) aq. HCI /0131
,IQ
COOH
The palladium-catalyzed addition of boronic ester (76) to 1methyl-4-iodopyrazole provides pyrazole Debenzylation with boron trifluoride etherate and ethanethiol, followed by hydrolysis and protonation, provides Example WO 01/34580 PCT/US00/30942 -53- Scheme 11 The following scheme illustrates a process for making Example a 2-substituted thiazole LTB 4 receptor antagonist: WO 01/34580 WO 0134580PCT[USOO/30942 -54- Scheme 11
N-
(76)
BF
3 -Et 2 O, EtSH_ 1) aq. UOH 2) HCI (84) (86)
~NOH
S
COOH
The palladium-catalyzed addition of boronic ester (76) to 2bromothizaole provides thiazole Debenzylation with WO 01/34580 PCT/US00/30942 boron trifluoride etherate and ethanethiol gives thiazole Hydrolysis and protonation provides Example (11).
Scheme 12 The following scheme illustrates a process for making Example a 4-substituted isoxazole LTB 4 receptor antagonist: WO 01/34580 WO 0134580PCTIUSOO/30942 -56- Scheme 12 1) PdCI 2 (dppf), Cs 2 00 3 toluene (76) COOMe 1) Me 3 SiI 2) aq. HCI 3) NaOH (88) COONa (12) The palladium-catalyzed addition of boronic ester (76) to 3, 5-dimethyl-4-iodoisoxazole provides oxazole (88).
Debenzylation with trimethylsilyl iodide, followed by hydrolysis and salt formation, provides Example (12).
WO 01/34580 WO 0134580PCT/USOO/30942 -57- Scheme 13 The following scheme illustrates a process for making Example a 2-substituted furan LTB 4 receptor antagonist: Scheme 13 Br, CH 2
CI
2 TBSCA, Imldazole '.OOMe Pd(PPh 3 aq. Na2CO,, TH-F 2) HCI OOOMe 3) NaOH
H
0 N COONa (13).
WO 01/34580 PCT/US00/30942 -58- Debenzylation of bromide (60) with boron tribromide provides phenol that is treated with tert-butyldimethylsilyl chloride and imidazole to give silyl ether The palladium-catalyzed addition of (92) to furan-2-boronic acid provides furan Hydrolysis and salt formation gives Example (13).
Scheme The following scheme illustrates a 3-substituted furan LTB 4 14 a process for making Example receptor antagonist: Scheme 14 COOMe (92) 0IB(OH), Pd(PPh 3 4 aq. Na 2
CO,
3
THF
1) aq. UOH 2) HCI 3) NaOH WO 01/34580 PCTIUSOO/30942 -59- The palladium-catalyzed addition of (92) to furan-3-boronic acid provides furan Hydrolysis and salt formation gives Example (14).
Scheme The following scheme illustrates a process for making Example a 3-substituted tetrahvdrcofiiran T ~rrrnrTThgT(T,,C- WO 01/34580 WO 0134580PCTIUSOO/30942 Scheme ;P B(OH)2 Pd(PPh 3 aq. Na 2 00 3
THF
H
2 Pd(C) (98) 0 OH N. COOMe (100) 1) aq. UOH 2) HCI 3) NaOH The palladium-catalyzed addition of bromide (60) to furan-3boronic acid provides furan Hydrogenation over a aladiuma catalyst gives tetrahydrofuran (100). Hydrolysis and salt formation gives Example WO 01/34580 PCT/US00/30942 -61- Scheme 16 The following scheme illustrates a process for making Example a 2-substituted pyrrolidine LTB 4 receptor antagonist: WO 01/34580 WO 0134580PCT/USOO/30942 -62- Scheme 16
B(OH),
Pd(PPh, 4 aq. NaCO 2
THF
COOM
H
2 Pd(C) (102)
OH
COOMe (104).
aq. LJOH 4 NOAI 0
COWL
HCI
(106) I
N
*HCI
COOH
(16) The palladium-catalyzed addition of bromide (60) to N-boc pyrrole-2-boronic acid provides pyrrole (102). Hydrogenation over a palL air, catalyst gives pyrrolidine (104).
Hydrolysis and salt formation gives pyrrolidine (106).
WO 01/34580 PCT/US00/30942 -63- Treatment with hydrochloric acid provides Example (16) as the hydrochloride salt.
Scheme 17 The following scheme illustrates a process for making Example a 3-substituted thiophene LTB 4 receptor antagonist: WO 01/34580 WO 0134580PCTUSOO/30942 -64- Scheme 17
B(OH),
Pd(PPh 3 eq. Na 2
CO
3
THF
(108) cI HO CNQ (110) known compound: RN# 152609-78-4 J. S. Sawyerat al., J. Med. Chein. 1995, 38,4411
K
2 C0 3 KI, DMVSO. 2-butanone (112) BBr 3
CH
2
CI
2
CN
1) NaOH 2) HCI (114) The palladium-catalyzed addition of bromide (58) to thiophene-3-boronic acid provides thiophene (108).
Alkvlation of known phenol (110)~ with (108) caaye by base provides thiophene (112). Debenzylation with boron WO 01/34580 PCT/US00/30942 tribromide gives thiophene (114).
protonation provide Example (17).
Hydrolysis and Scheme 18 The following scheme illustrates a process for making Example a 5-substituted 1,2,3,4-thiatriazole LTB 4 receptor antagonist: WO 01/34580 WO 0134580PCTIUSOOI3O942 -66- Scheme 18 HOC 0": COOMe 1-bromo-3-d'hloropropane KC0,, DMF 1) K200., Nal, 2-btflanone I H knowni compound: RN 37470-83.0 (118) ',tY'A 3 onor,1 umI- (120) O H 2 1) HS-"S
TSOH
2) NaH. DMF, I-fMPA 3) piperldine IMe 2) NaN 3 1) BF,-E1 2 0. CH,01 2 2) aq. NaGH 3) eq. HCI (122) (124)
H
N. I S 0 0 0
OOOH
(18) Reference for formationi of dithioacids: N. C. Gonnef Ia at al. Syn. Com mun. 1979,.17 Reference for formation of 5-substituted 1 .2.3,4-thiatriazoles from dithicacids: S. 1. Ikeda et al.. Synthesis 1990,415 Phenol (30) is alkylated with l-bromo--3-chloropropane to give chloride (116), that is in turn to be treated with known aldehyde (1180) and-A a base, followed bDy bt:!izyiation with benzyl bromide and a base, to provide aldehyde (120).
WO 01/34580 PCT/US00/30942 -67- From aldehyde (120) is made the thioacetal by treatment with 1,2-ethanedithiol. The resulting thioacetal is then to be treated with base to provide the thioacid. Treatment with piperidine makes piperidinium salt (122). By the teaching of Ikeda, infra, (the disclosure of which is incorporated herein by reference) treatment of (122) with 2chloropyridinium methyl iodide followed by azide ion will give the 1,2,3,4-thiatriazole (124). Debenzylation with boron trifluoride etherate and ethanethiol, followed by hydrolysis and protonation, will provide the product of Example (18).
Scheme 19 The following scheme illustrates a process for making Example a 4-substituted 1,2,3-thiadiazole LTB 4 receptor antagonist: WO 01/34580 WO 0134580PCTIUSOO/30942 -68- Scheme 19 NHNHCOOEt COOMe SOC1 2 (128) 00 0- 1TO-COOMe (130) I) BF, Et 2 O, EtS- 2) aq. NizOH 3) aq. H-CI
COOH
(19) Ref erence for I .2,3-thiadlazole formation: E. W. Thomas et al., J. Med. Chain. 1985. 28, 442.
Treatment of acetophenone (32) with ethyl carbazate will give the hydrazone (128). Use of thionyl chloride by the method of Thomas et. al. (infra., the disclosure of which is incorporated herein by reference) will give an intermediate 1,2,3-thiadiazole (130), that is to be debenzylated with WO 01/34580 PCT/US00/30942 -69boron trifluoride etherate and ethanethiol, then hydrolyzed and protonated to give the product of Example (19).
Scheme The following scheme illustrates a process for making Example a 3-substituted 1,2,5-thiadiazole LTB 4 receptor -a104- WO 01/34580 WO 0134580PCTIUSOO/30942 Scheme
CI
N ''N CI" SN C1 r COOMe (trithia7vl triethInridAl n9 COOMe 1) BF, 3 Et 2 O, EtSH 2) aq. NaOH 3) aq. HCI (132) Reference for 1,2.5-thiadiazate formation: E. W. Thomas et al., J. Med. Chem. 1985, 28.442.
Alkyne (62) is to be treated with trithiazyl trichioride by the method of Thomas et. al. (infra., the disclosure of which is incorporated herein by reference) to provide thiadiazole (132). Debenzylation with boron trifluoride etherate and ethanethiol, followed by hydrolysis and protonation, will provide the product of Example WO 01/34580 PCT/USO0/30942 -71- Scheme 21 The following scheme illustrates a process for making Example a 2-substituted 1,3,4-thiadiazole LTB 4 receptor antagonist: WO 01/34580 WO 0134580PCT/USOO/30942 -72- Scheme 21
~N'N
Br known compound, RN 61929-24-6 PCT WO 9730981 PdCI 2 (dppf), CS 2
CQ
3 toluene 1) BF 3 -Et 2 O, EtSH 2) aq. NaOH 3) aq. HOI (76) (134) The palladium-catalyzed addition of boronic ester (76) to 2bromo-l,3, 4-thiadiazole will provide ester (134).
Debenzylation with boron trifluoride etherate and ethanethiol, followed by hydrolysis and protonation, will provide the product of Example (21).
WO 01/34580 PCT/US00/30942 -73- Scheme 22 The following scheme illustrates a process for making Example a 5-substituted isothiazole LTB 4 receptor antagonist: WO 01/34580 WO 0134580PCT/USOO/30942 -74- Scheme 22 PnoTn compounld: RN 21 6971-00-5 PTWO 9855480 Pd(PPh3J 4 Na 2
CO
3 EtOH, H 2 0
K
2 C0 3 KI, DMSO, (136) 0 0.
COOMe (138) 2) aq. NaOH 3) aq. HCI
COOH
(22) The palladium-catalyzed addition of bromide (58) to 3acid will provide isothiazole (136). Alkylation. of phenol (30) with (136) catalyzed by base will provide isothiazole (138). Debenzylation with boron trifluoride etherate and ethanethiol, followed by hydrolysis and protonation, will provide the product of Example (22).
WO 01/34580 WO 0134580PCTIUSOOI30942 Scheme 23 The following scheme illustrates a process for making Example a 2-substituted oxazole LTB 4 receptor antagonist: Scheme 23 Br known compound: RN 125533-82-6 R. D. Miller et al., Chem. Mater. 1994, 1023.
PdCI 2 (dppo), CS 2
CO
3 toluene (76) (140) 1) BF., Et,O, EtSH 2) aq. NaOH 3) aq. HCI
COOH
(23) The palladium-catalyzed addition of boronic ester (76) to 2bromooxazole will provide oxazole (140). Debenzylation with boron trifluoride etherate and ethanethiol, followed by hydrolysis and protonation, will provide the product of Example (23).
WO 01/34580 PCT/USOO/30942 -76- Scheme 24 The following scheme illustrates a process for making Example a 3-substituted thiophane LTB 4 receptor antagonist: WO 01/34580 WO 0134580PCT/USOO/30942 -77- Scheme 24 Et 3 SiH. TFA, benzene (114)
CN
1) aq. NaOH 2) HCI (142)
COOH
(24) Reference for formation of tetrahydrothiophenes: D. N. Kursanov et al. Tetrahedron 1975, 31, 311 Thiophene (114) may be reduced in the presence of triethylsilane and trifluoroacetic acid by the method of Kursanov et. al. (infra., the disclosure of which is incorporated herein by reference) to provide the thiophane (142). Hydrolysis and protonation will provide the product of Example (24).
WO 01/34580 PCT/US00/30942 -78- V. PREPARATIVE EXAMPLES 1 TO 17: Example 1 Preparation of 2-(3-[3-(2-Ethyl-5-hydroxy-4-oxazol-4-ylphenoxy)propoxy]-2-propyl-phenoxy)Denzoic acia.
0 H 0O known compound: RN# 156005-61-7 R. W. Harper et al., J. Med. Chem. 1994, 37(15), 2411-20 A. Preparation of 1-[2-benzyloxy-4-( ethylphenyl]ethanone.
A mixture of l-[2-hydroxy-4-(3-chloropropoxy)-5ethylphenyl]ethanone (26.1 g, 102 mmol), cesium carbonate (33.4 g, 103 mmol), and benzyl bromide (12.2 ml, 103 mmol), in N,N-dimethylformamide (300 mL) was stirred for 5 h at room temperature. The mixture was diluted with ethyl acetate and washed four times with water. The organic layer was dried (sodium sulfate), filtered, and concentrated in vacuo. The resulting oil was triturated with ethyl acetate and hexane, allowed to stand for 18 h, then cooled at 0 °C for 3 h. The resulting precipitate was collected via vacuum filtration to provide 24.3 g of the title compound as white crystals: mp 60-61 oC. H NMR (CDC13) 6 7.68 (s, 1H), 7.40 5H), 6.48 1H), 5.17 2H), 4.13 J 6 Hz, 2H), 3.75 J 6 HY, 2H), 2.56 3H), 2.55 J 7 Hz, 2H), 2.26 (quintet, J 6 Hz, 2H), 1.16 J WO 01/34580 PCT/US00/30942 -79- 7 Hz, 3H); TOF MS ES exact mass calculated for
C
20
H
24 C10 3 m/z 347.1414. Found: 347.1402; IR (CHC1 3 -1 cm 1659, 1602, 1266.
Anal. Calrd fnr C Cn- C 69.2; Fcd C, 69.30; H, 6.52.
O .4 H O 0- -CI COOMe known compound: RN# 152609-76-2 J. S. Sawyer et al., J. Med. Chem. 1995, 38,4411 COOMe B. Preparation of 2-{3-[3-(4-acetyl-5-benzyloxy-2ethylphenoxy)propoxy] -2-propyl-phenoxy)benzoic acid methyl ester.
A mixture of 1-[2-benzyloxy-4-(3-chloropropoxy)-5ethylphenyl]ethanone (7.27 g, 21.0 mmol) and sodium iodide (3.14 g, 23.1 mmol) in 2-butanone (100 mL) was heated at reflux for 18 h. The mixture was cooled to room temperature, filtered, and concentrated in vacuo. The residue was dissolved in N,N-dimethylformamide (100 mL) and treated with 2-(3-hydroxy-2-propylphenoxy)benzoic acid methyl ester (6.0 g, 21 mmol) and potassium carbonate (3.2 g, 23 mmol) at room temperature for 15 h. The mixture was WO 01/34580 WO 0134580PCTIUSOO/30942 diluted with ethyl acetate and washed four times with water and once with saturated sodium chloride solution. The organic layer was dried (sodium sulfate), filtered, and concentrated in vacuo. Chromatography (silica gel, ethyl acetate/90% hexane) of the residue provided 9.2 g 1 of the title compound as a colorless oil. H NMR (CDC1 3 8 7.88 J =9 Hz, 1H), 7.69 1H), 7.38 (in, 6H), 7.12 JT 8 Hz, 1H), 7.07 J 8 Hz, 1H), 6.80 J 8 Hz, 1H), 6.67 J 8 Hz, 1H), 6.50 1H), 6.44 J 9 Hz, 1H), 5.14 2H), 4.20 (in, 4H), 3.83 (s, 3H), 2.65 J 7 Hz, 2H), 2.57 J 7 Hz, 2H), 2.56 3H), 2.32 (quintet, J 6 Hz, 2H), 1.55 (hextet, J 7 Hz, 2H), 1.15 J 8 Hz, 3H), 0.90 J 7 Hz, 3H); IR -1 (CHCl 3 cm 2965, 1726, 1602, 1461.
Anal. Calcd for C 3 7
H
40 0 7 C, 74.48; H, 6.76. Found: C, 74.39; H, 6.77.
COOMe HOj C. Preparation of 2-(3-(3-[5-benzyloxy-2-ethyl-4-(2hydr-o-ryacelty'1) p'herLoxy] propoxy) -2-propylphenoxy)benzoic acid methyl ester.
WO 01/34580 PCT/US00/30942 -81- A mixture of 2-{3-[3-(4-acetyl-5-benzyloxy- 2 ethylphenoxy)propoxy]-2-propyl-phenoxy}benzoic acid methyl ester (5.31 g, 8.89 mmol) and water (10 mL) in acetonitrile mL) was treated with trifluoroacetic acid (1.4 mL), 18 mmol) and [bis(trifluoroacetoxy)iodo]benzene (7.65 g, 17.8 mmol). The resulting mixture was heated at reflux for 4 h then concentrated in vacuo. The residue was dissolved in methylene chloride and washed once with water. The aqueous layer was extracted twice with fresh portions of methylene chloride. The combined organic layers were washed three times with saturated sodium bicarbonate solution, once with saturated sodium chloride solution, dried (sodium sulfate), filtered, and concentrated in vacuo. Chromatography (silica gel, 20% ethyl acetate/80% hexane) of the residue provided 1 1.68 g of the title compound as a brown oil. H NMR (CDC1 3 8 7.92 1H), 7.88 J 9 Hz, 1H), 7.40 (m, 6H), 7.12 J 9 Hz, 1H), 7.05 J 9 Hz, 1H), 6.79 J 8 Hz, 1H), 6.66 J 8 Hz, 1H), 6.50 1H), 6.43 J 8 Hz, 1H), 5.15 2H), 4.65 2H), 4.22 (m, 4H), 3.83 3H), 2.65 4H), 2.34 (quintet, J 6 Hz, 2H), 1.55 (hextet, J 7 Hz, 2H), 1.17 J 8 Hz, 3H), 0.89 J 8 Hz, 3H); TOS MS ES exact mass calculated for C 37
H
41 0 8 m/z 613.2801. Found: 613.2833.
WO 01/34580 PCT/US00/30942 -82- HO O
S
1 COOMe 1N 0"V /N COOMe D. Preparation of 2-{3-[3-(5-benzyloxy-2-ethyl-4-oxazol-4yl-phenoxy)propoxy] -2-propylphenoxy)benzoic acid methyl ester.
To a solution of 2-(3-{3-[5-benzyloxy-2-ethyl-4-(2hydroxyacetyl)phenoxy]propoxy} -2-propylphenoxy)bnzoic acid methyl ester (1.39 g, 2.27 mmol) in methylene chloride mL) cooled to -78 oC was added triflic anhydride (0.57 mL, 3.4 mmol) and 2,6-lutidine (0.40 mL, 3.4 mmol). The resulting mixture was stirred for 1 h then poured into ether and water. The organic layer was separated and washed once with saturated sodium chloride solution, dried (sodium sulfate), filtered, and concentrated in vacuo. The residue was dissolved in a 2:1 mixture of formamide/N,Ndimethylformamide (9 mL) and heated at 120 oC in a sealed tube for 4 h. The mixture was cooled to room temperature and diluted with ethyl acetate. The mixture was washed four times with water, once with saturated sodium chloride solution, dried (sodium sulfate), filtered, and concentrated in vacuo. Chromatography (silica gel, 10% ethyl hexane) of the residue provided 89 mg of the title product as a colorless oil. H NMR (CDC1 3 6 7.92 1H), WO 01/34580 PCT/US00/30942 -83- 7.85 1H), 7.83 2H), 7.35 6H), 7.03 J 8 Hz, 1H), 7.00 J 8 Hz, 1H), 6.73 J 8 Hz, 1H), 6.62 J 8 Hz, 1H), 6.52 1H), 6.35 J 8 Hz, 1H), 5.07 2H), 4.14 4H), 3.76 3H), 2.61 4H), 2.26 (quintet, J 6 Hz, 2H), 1.48 (hextet, J 7 Hz, 2H), 1.15 J 8 Hz, 3H), 0.84 J 8 Hz, 3H).
COOMe N H COOMe E. Preparation of 2-(3-[3-(2-ethyl-5-hydroxy-4-oxazol-4-ylphenoxy)propoxy]-2-propylphenoxy)benzoic acid methyl ester.
To a solution of 2-{3-[3-(5-benzyloxy-2-ethyl-4-oxazol-4-ylphenoxy)propoxy]-2-propylphenoxy}benzoic acid methyl ester (89 mg, 0.14 mmol) in ethanethiol (2 mL) was treated with boron trifluoride etherate (0.27 mL, 2.2 mmol) at room temperature for 4 h. The solution was poured into ether and washed once with water, once with saturated sodium bicarbonate solution, once with saturated sodium chloride solution, dried (sodium sulfate), filtered, and concentrated in vacuo. Chromatography (silica gel, 15% ethyl hexane) of the residue provided 34 mg of the title product as a light brown oil. H NMR (CDC13) 8 7.99 J i Hz, 1H), 7.90 J 1 Hz, 1H), 7.88 (dd, J 8, 2 Hz, 1H), 7.38 J 7 Hz, 1H), 7.15 1H), 7.10 J 9 WO 01/34580 WO 0134580PCT/USOO/30942 -84- Hz, 1H), 7.06 Cd, J 9 Hz, 1H) 6. 81 J 9 Hz, 1H) 6.70 J 9 Hz, 1H), 6.52 1H), 6.44 J 9 Hz, 1H), 4.20 (in, 4H), 3.83 3H), 2.65 J 8 Hz, 2H), 2.58 J 8 Hz, 2H), 2.33 (quintet, J 6 Hz, 2H), 1.55 (hextet, J 7 Hz, 2H), 1.17 J 8 Hz, 3H), 0.91 J 8 Hz, 3H); MS ES+ Wne =532 (p 1).
/N H COOMe /N H
COOH
F. Preparation of 2-(3-(3-(2-ethyl-5-hydroxy-4-oxazol-4-y1phenoxy)propoxy] -2-propylphenoxy)benzoic acid.
To a solution of 2-{3-[3-(2-ethyl-5-hydroxy-4-oxazol-4-ylphenoxy) propoxy] -2-propylphenoxy)benzoic acid methyl ester (89 mg, 0.14 inmol) in methanol (2 mL) was added 1 M lithium hydroxide solution (0.28 mL) and the resulting mixture warmed at 60 0 C for 3.5 h. The mixture was cooled to room temperature and concentrated in vacuo. The aqueous residue was diluted with water and the pH adjusted to The mixture was extracted three times with methylene chloride.
The combined organic extracts were dried (sodium sulfate), filtered, and concentrated in vacuo to provide 27 mg (92%) of the title compound as a yellow solid. 1H NMR (DMSO-d 6 8 12.83 Cbs, 1H), 10.12 Cbs, 1H), 8.39 Cs, lH), 8.25 Cs, 1H), 7.78 Cdd, J 8, 1 Hz, 1H), 7.64 1H), 7.47 Ct, J WO 01/34580 WO 0134580PCTIUSOO/30942 8 Hz, IH) 7. 16 (in, 2H) 6. 80 J 8 Hz, 2H) 6. 56 (s, 1H) 6. 35 J 8 Hz, 1H) 4. 20 J 6 Hz, 2H) 4. 12 J 6 Hz, 2H); 2.54 (in, 4H), 2.24 (quintet, J 6 Hz, 2H), 1.43 (hextet, J 8 Hz, 2H), 1.10 J 8 Hz, 3H), 0.80 J 8 Hz, 3H); TOF MS ES exact mass calculated for C 30
H
32 N0 7 m/z 518.2179. Found: 518.2206; IR -1 (KBr, cm 2961, 1696, 1460, 1222.
Anal. Calcd for C 30
H
3 1 N0 7 C, 69.62; H, 6.04; N, 2.71.
Found: C, 68.71; H, 5.82; N, 2.65.
Excample 2 Preparation of 2- [2-Ethyl-5-hydroxy-4- (3H-imidazol-4yl)ph~enoxyl propoxy) -2-propyl-phenoxy)benzoic acid hydrochloride.
A. Preparation of 2-(3-(3-C5-benzyloxy-4-(2-chloroacetyl)- 2-ethyiphenoxy] propoxy) -2-propyiphenoxy) benzoic acid methyl ester.
To a solution of 2-(3-[3-(4-acetyl-5-benzyloxy-2ethyiphenoxy) propoxy] -2-propyl-phenoxy)benzoic acid methyl WO 01/34580 PCT/US00O/30942 -86ester (3.04 g, 5.09 mmol) in tetrahydrofuran (50 mL) cooled to -78 oC was added a solution of 1 M lithium hexamethyldisilazide in tetrahydrofuran (11.2 mL, 11.2 mmol) portion wise. After stirring for 20 min, trimethylsilyl chloride (2.6 mL, 20 mmol) was added and the mixture warmed to 0 oC and stirred for 30 min. The mixture was evaporated solution was filtered and concentrated in vacuo. The residue was dissolved in tetrahydrofuran (50 mL), cooled to 0 oC, and treated with N-chlorosuccinimide (750 mg, 5.6 mmol). The mixture was warmed to room temperature and stirred for 30 min, then heated at reflux for 2 h. The mixture was cooled to room temperature and treated with water (4 mL) and a solution of 1 N tetra-n-butylammonium fluoride in tetrahydrofuran (6 mL). After stirring for min the mixture was diluted in ether and washed once with water, once with saturated sodium chloride solution: dried (sodium sulfate), filtered, and concentrated in vacuo.
Chromatography (silica gel, 10% ethyl acetate/90% hexane) of the residue provided 1.94 g of the title compound as a white solid. H NMR (CDC13) 8 7.89 J 8 Hz, 1H), 7.77 1H), 7.40 6H), 7.12 J 9 Hz, 1H), 7.06 J 8 Hz, 1H), 6.80 J 8 Hz, 1H), 6.66 J 8 Hz, 1H), 6.49 1H), 6.43 J 8 Hz, 1H), 5.15 2H), 4.68 (s, 2H), 4.20 J 6 Hz, 4H), 3.82 3H), 2.65 J 7 Hz, 2H), 2.59 J 7 Hz, 2H), 2.32 (quintet, J 6 Hz, 2H), 1.54 (hextet, J 8 Hz, 2H), 1.16 J 8 Hz, 3H), 0.89 J 7 Hz, 3H); TOF MS ES exact mass calculated for C 37
H
40
CIO
7 m/z 631.2463. Found: 631.2470; IR -1 (CHC1 3 cm 2964, 1720, 1603, 1461.
Anal. Calcd for C 37
H
3 9 C10 7 C, 70.41; H, 6.23. Found: C, 70.04; H, 5.97.
WO 01/34580 PCT/US00/30942 -87- 0 CICOOMe I" I COOMCOOMe
S
0 0 0 Me 0 COOMe B. Preparation of 2-(3-(3-[5-benzyloxy-4-(2-benzylsulfanyl- 3H-imidazol-4-yl)-2-ethyl-phenoxy]propoxy}-2propylphenoxy)benzoic acid methyl ester.
A mixture of 2-(3-{3-[5-benzyloxy-4-(2-chloroacetyl)-2ethylphenoxy]propoxy}-2-propylphenoxy)benzoic acid methyl ester (800 mg, 1.27 mmol), 2-benzyl-2-thiopseudourea hydrochloride (313 mg, 1.52 mmol), sodium iodide (77 mg, 0.51 mmol), and potassium carbonate (700 mg, 5.06 mmol) in N,N-dimethylformamide (20 mL) was treated at 80 oC for 6 h.
The mixture was cooled, diluted with diethyl ether, and washed once with water. The organic layer was dried (sodium sulfate), filtered, and concentrated in vacuo.
Chromatography (silica gel, 30% ethyl acetate/70% hexane) of the residue provided 376 mg of the title compound as a yellow amorphous solid. H NMR (CDC13) 8 7.89 J 8 Hz, 1H), 7.36 9H), 7.20 5H), 7.21 J 9 Hz, 1H), 7.06 J 8 Hz, 1H), 6.79 J 8 Hz, 1H), 6.67 J 8 Hz, 1H), 6.55 1H), 6.43 J 8 Hz, 1H), 5.07 (s, WO 01/34580 WO 0134580PCTUSOO/30942 -88- 2H), 4.21 J 6 Hz, 2H), 4.18 J 6 Hz, 2H), 4.10 Cs, 2H), 3.83 Cs, 3H), 2.63 (in, 4H), 2.31 (quintet, J 6 Hz, 2H) 1. 55 Chextet, J 7 Hz, 2H) 1. 18 J 8 Hz, 3H), 0.90 J 7 Hz, 3H); TOF MS ES exact mass calculated for C 4 5
H
47
N
2 0 6 S m/z 743.3155. Found: 43 3i 2; !R (CHC i 3 tcmu 2 "3 1720, 2S 2, 1153.
Anal. Calcd for C 45
H
4 6
N
2 0 6 S: C, 72.75; H, 6.24; N, 3.77.
Found: C, 72.69; H, 6.17; N, 3.56.
C. Preparation of 2- [4-(2-benzylsulfanyl-3H-imidazol- 4-yl) -2-ethyl-5-hydroxypbenoxy]propoxy) -2propylphenoxy)benzoic acid methyl ester.
A solution of 2 'L3-L 5-brzl~y n! imidazol-4-yl) -2-ethyl-phenoxylpropoxyl -2- WO 01/34580 PCT/US00/30942 -89propylphenoxy)benzoic acid methyl ester (360 mg, 0.49 mmol) in ethanethiol (7 mL) was treated with boron trifluoride etherate at room temperature for 3.5 h. The mixture was diluted with diethyl ether and water. The organic layer was separated and washed with saturated sodium bicarbonate solution, dried (sodium sulfate), filtered, and concentrated in vacuo. Chromatography (silica qel, 20% ethyl hexane) of the residue provided 154 mg of the title compound as an orange oil. H NMR (CDC13) 6 7.85 J 8 Hz, 1H), 7.36 J 7 Hz, 1H), 7.20 7H), 7.12 1H), 7.05 3H), 6.79 J 8 Hz, 1H), 6.65 J 8 Hz, 1H), 6.54 1H), 6.41 J 8 Hz, 1H), 4.20 2H), 4.17 4H), 3.82 3H), 2.62 J 8 Hz, 2H), 2.54 (q, J 7 Hz, 2H), 2.30 (quintet, J 6 Hz, 2H), 1.53 (hextet, J 8 Hz, 2H), 1.14 J 7 Hz, 3H), 0.89 J 8 Hz, 3H); TOF MS ES exact mass calculated for C 3 8
H
4 1
N
2 0 6 S m/z 653.2685. Found: 653.2669.
Anal. Calcd for C 3 8
H
40
N
2 0 6 S: C, 69.92; H, 6.18; N, 4.29.
Found: C, 69.44; H, 6.25; N, 3.99.
WO 01/34580 PCT/US00/30942
S
SN H
H
17- N H I I
II
O O O
N.
COOH
D. Preparation of 2-(3-(3-[2-ethyl-5-hydroxy-4-(3Himidazcl-4-yl)phanoxy propoxy -2-propyl-phenoxy)benzoic acid hydrochloride.
A solution of 2-(3-(3-[4-(2-benzylsulfanyl-3H-imidazol-4yl)-2-ethyl-5-hydroxyphenoxy]propoxy}-2propylphenoxy)benzoic acid methyl ester (154 mg, 0.235 mmol) in methanol (3 mL) was'treated with 1 N lithium hydroxide solution at 60 oC for 3.5 h. The mixture was cooled to room temperature and concentrated in vacuo. The solution was diluted with water and adjusted to pH 4. The aqueous solution was extracted three times with methylene chloride.
The combined organic layers were dried (sodium sulfate), filtered, and concentrated in vacuo. The residue was dissolved in ethanol (3 mL) and treated with 0.2 N sodium hydroxide solution (1 mL) and Raney nickel (75 mg) at 75 °C for 4 h. The mixture was cooled to room temperature,
TM
filtered through Celite and the filtrate concentrated in vacuo. The residue was diluted with water and adjusted to WO 01/34580 PCT/US00/30942 -91pH 2 with 1 N hydrochloric acid. The resulting precipitate was collected via vacuum filtration to provide 27 mg (21%) of the title compound. TOF MS ES exact mass calculated for C 30
H
33
N
2 0 6 m/z 517.2339. Found: 517.2340.
Example 3 Preparation of 2-{3-[3-(2-Ethyl-5-hydroxy-4-thiazol-4-ylphenoxy)propoxy]-2-propyl-phenoxy)benzoic acid.
COOMe
N
COOMe A. Preparation of 2-{3-[3-(5-benzyloxy-2-ethyl-4-thiazol-4yl-phenoxy)propoxy]-2-propylphenoxy}benzoic acid methyl ester.
A mixture of 2-(3-{3-[5-benzyloxy-4-(2-chloroacetyl)-2ethylphenoxy]propoxy}-2-propylphenoxy)benzoic acid methyl ester (500 mg, 0.792 mmol), thioformamide (20 mL, 8.0 mmol), and magnesium carbonate in dioxane (10 mL) was heated at reflux for 2 h. The mixture was cooled to room temperature and diluted with diethyl ether and 0.2 M sodium hydroxide solution. The organic layer was separated, washed with saturated sodium chloride solution, dried (sodium sulfate), filtered, and concentrated in vacuo. Chromatography (silica gel, 10% ethyl acetate/90% hexane) of the residue provided WO 01/34580 PCTUS00/30942 -92- 1 254 mg of the title compound as a colorless oil. H NMR (CDC1 3 6 8.91 1H), 8.11 1H), 7.87 (dd, J 8, 1 Hz, 1H), 7.84 J 1 Hz, 1H), 7.40 6H), 7.08 2H), 6.80 J 8 Hz, 1H), 6.68 J 8 Hz, 1H), 6.62 (s, 1H), 6.43 J 8 Hz, 1H), 5.16 2H), 4.21 J 6 4) 3.3 3" 2.6 A4- 9 2 (quintet, J 6 Hz, 2H), 1.56 (hextet, J 8 Hz, 2H), 1.21 J 7 Hz, 3H), 0.90 J 7 Hz, 3H); TOF MS ES exact mass calculated for C 38
H
4 0
NO
6 S m/z 638.2576. Found: -1 638.2579. IR (CHC1 3 cm 2964, 1719, 1563, 1461.
S
COOMe
H
COOMe B. Preparation of 2-(3-[3-(2-ethyl-5-hydroxy-4-thiazol-4yl-phenoxy)propoxy]-2-propylphenoxy}benzoic acid methyl ester.
A solution of 2-{3-[3-(5-benzyloxy-2-ethyl-4-thiazol-4-ylphenoxy)propoxy]-2-propyl-phenoxy}benzoic acid methyl ester (243 mg, 0.366 mmol) in ethanethiol (7 mL) was treated with boron triluo 1 ride etherate at room temperature for 4 h. The mixture was diluted with diethyl ether, washed once with WO 01/34580 WO 0134580PCTUSOOI30942 -93water, once with saturated sodium bicarbonate solution, dried (sodium sulfate), filtered, and concentrated in vacuo.
Chromatography (silica gel, 15% ethyl acetate/85% hexane) of the residue provided 131 mg of the title compound as a colorless oil. H NNR (CDCl 3 8 8.88 J 1 Hz, 1H), 7.88 (dd, J 8, 1 Hz, 1H), 7.44 J 1 Hz, 1H), 7.38 (in, 2H), 7.06 (mf, Zki), 6b6-L td, J 8 Hz, 1H), 6.68 J 8 Hz, 1H), 6.55 1H), 6.43 J 8 Hz, 1H), 4.21 J= 6 Hz, 4H), 3.83 3H), 2.63 (in, 4H), 2.33 (quintet, J 6 Hz, 2H), 1.56 (hextet, J 8 Hz, 2H), 1.19 Ct, J =8 Hz, 3H), 0.91 J 7 Hz, 3H); TOF MS ES exact mass calculated for C 31
H
34 N0 6 S m/z =548.2107. Found: 548.2085.
COOMe /N H S N' COOH C. Preparation of (2-ethyl-5-hydroxy-4-thiazol-4yl-phenoxy)propoxyj -2-propylphenoxy~benzoic acid.
A solution of 2-(3-(3-(2-ethyl-5-hydroxy-4-thiazol-4-ylphenoxy) propoxy) -2-propylphenoxylbenzoic acid methyl ester (130 mng, 0.236 nmol) in methanol (4 mL,) was treated with 1 M lithium hydroxide solution at 60 0 C for 3 h. The mixture was cooled to room temperature, concentrated in vacuo, and WO 01/34580 WO 0134580PCTIUSOO/30942 -94diluted with water. The solution was adjusted to pH and extracted three times with methylene chloride. The combined organic layers were dried (sodium sulfate), filtered, and concentrated in vacuo. The residue was dissolved in a minimum of methylene chloride and hexane was added until the solution became cloudy. The mixture was concentrated slowly 1 Iti g-v w IL~j %Iv'oI u.J LIIu L>LLe comTpoundU.
(CDCl 3 8 8.90 1H) 8.23 (dd, J 1 Hz, 1H), 7.41 (in, 2H), 7.38 1H) 7.29 (in, 2H), 6.82 J 8 Hz, 1H), 6.71 J 8 Hz, 1H), 6.62 J 8 Hz, 1H), 6.54 (s, 1H), 4.25 J 6 Hz, 2H), 4.22 J =6 Hz, 2H), 2.59 (mn, 4H), 2.35 (quintet, J 6 Hz, 2H), 1.50 (hextet, J 8 Hz, 2H), 1.19 J 7 Hz, 3H), 0.88 J 8 Hz, 3H); TOF MS ES exact mass calculated for C 30
H
32 N0 6 S ni/Z -1 =534.1950. Found: 534.1957. IR (CHCl 3 cm 2965, 1738, 1454.
Anal. Calcd for C 30
H
31 N0 6 S: C, 67.52; H, 5.86; N, 2.62.
Found: C, 67.19; H, 5.72; N, 2.53.
Example 4 Preparation of 2- [2-Ethyl-5-bydroxy-4-(2H-pyrazol-3yl )phenoxy] propoxy) -2-propyl-phenoxy)benzoic acid.
WO 01/34580 WO 0134580PCTUSOO/30942 COOMe
NN
COOMe A. Preparation of 2-(3-f3-C5-benzyloxy-4-(3dimethylaminoacryloyl) -2-ethyl-phenoxyl propoxy) -2propylphenoxy)benzoic acid methyl ester.
A mixture of 2-(3-{3-[4-acetyl-5-benzyloxy-2ethylphenoxyipropoxy}-2--propylphenoxy)benzoic acid ittetihyl ester (3.07 g, 5.04 rruol) and dimethylformamide dimethylacetal (0.9 rnL, 7 mmol) in N,N-dimethylformamide (3 niL) was heated at 110-120 OC for 35 h. The mixture was cooled to room temperature and diluted with a mixture of ethyl acetate and 1 N hydrochloric acid. The organic layer was separated, washed twice with water, once with saturated sodium chloride solution, dried (sodium sulfate), filtered, and concentrated in vacuo. Chromatography (silica gel, ethyl acetate/70% hexane to ethyl acetate) of the residue provided 2.1 g of the title compound as a yellow oil.
TOF MS ES exact mass calculated for C 4 0
H
4 6 N0 7 Mlz -1 -652.3274. Found: 652.3270. IR (CHCl 3 cm 2965, 1720, 1605.
Anal. Calcd for CAnHAN-,: C, 73.71; H, 6.96; N, 2.15.
Found: C, 73.72; H, 6.95; N, 2.18.
WO 01/34580 PCT/US00/30942 -96- SCOOMe
N-NH
COOH
B. Preparation of 2-(3-{3-[5-benzyloxy-2-ethyl-4-(2Hpyrazol-3-yl)phenoxylpropoxy)-2-propylphenoxy)benzoic acid.
A solution of 2-(3-{3-[5-benzyloxy-4-(3dimethylaminoacryloyl)-2-ethyl-phenoxylpropoxy}-2propylphenoxy)benzoic acid methyl ester (550 mg, 0.843 mmol in methanol (30 mL) was treated with 1 M lithium hydroxide solution at 60 oC for 3 h. The mixture was cooled to room temperature and diluted with ethyl acetate and 0.5 M hydrochloric acid. The organic layer was separated, washed with saturated sodium chloride solution, dried (sodium sulfate), filtered, and concentrated in vacuo. The residue was dissolved in methanol (15 mL) and treated with water (4 mL) and hydrazine monohydrate (0.50 mL, 7.7 mmol) at reflux for 3 h. The mixture was diluted with ethyl acetate and 1 N hydrochloric acid. The organic layer was separated, washed with saturated sodium chloride solution, dried (sodium sulfate), filtered and concentrated in vacuo.
Chromatography (30% ethyl acetate/69% hexane/l% acetic acid) of the residue provided 350 mg of the title compound as the acetate salt. A portion of this material was freebased with sodium bicarbonate to provide an analytical WO 01/34580 PCTUSOO/30942 -97sample. H NMR (CDCl 3 5 8.20 (dd, J 8, 2 Hz, 1H), 7.55 1H), 7.44 1H), 7.38 5H), 7.15 Cm, 2H), 6.78 (d, J 8 Hz, 1H), 6.65 J 8 Hz, 1H), 6.61 J 8 Hz, 1H), 6.58 1H), 6.55 Cbs, 1H), 5.18 2H), 4.22 J 6 Hz, 2H), 4.17 t, J 6 Hz, 2H), 2.58 Cm, 4H), 2.30 (quintet, J 6 Hz, 2H), 1.47 (hextet, J 8 Hz, 2H), 1.18 J 7 Hz, 3H), 0.88 J 8 Hz, 3H); TOF MS ES exact mass calculated for C 37
H
3 9
N
2 0 6 m/z 607.2808.
-1 Found: 607.2831. IR (CHC 3 cm 2965, 1739, 1604, 1454.
Anal. Calcd for C 37
H
38
N
2 0 6 C, 73.25; H, 6.31; N, 4.62.
Found: C, 73.31; H, 6.30; N, 4.62.
-N'H
COOH
N N H H
COOH
C. Preparation of 2-(3-(3-[2-ethyl-5-hydroxy-4-C2H-pyrazol- 3-yl)phenoxy]prapoxy)-2-propylphenoxy)benzoic acid.
A solution of 2-C3-(3-[5-benzyloxy-2-ethyl-4-C2H-pyrazol-3yl)phenoxy]propoxy}-2-propylphenoxy)benzoic acid (300 mg, 0.490 mmol) in ethanethiol (2.5 ml) was treated with boron trifluoride etherate (2 FL) aL room LemiperaLure for 3 h, at which time an additional portion of boron trifluoride WO 01/34580 WO 0134580PCTIUSOO/30942 -98etherate (1 mL) was added and stirring resumed for an additional 1 h. The mixture was diluted with diethyl ether and water. The organic layer was separated, washed with water, dried (sodium sulfate), filtered, and concentrated in vacuo. Chromatography (silica gel, 15% ethyl hexane to 60% ethyl acetate/40% hexane) of the residue '-3cA IA~.f the titlp c-omound as a white solid.
H NNR (CDCl 3 8 8.23 J 8 Hz, 1H), 7.61 1H), 7.42 J 7 Hz, 1H), 7.30 1H), 7.19 J 8 Hz, 1H), 7.15 J 8 Hz, 1H), 6.81 J =8 Hz, 1H), 6.69 J= 8 Hz, 1H), 6.61 lH), 6.60 J =8 Hz, 1H), 6.54 (s, 1H), 4.20 (in, 4H), 2.58 (in, 4H), 2.33 (quintet, J 6 Hz, 2H), 1.48 (hextet, J 8 Hz, 2H), 1.17 J 8 Hz, 3H), 0.86 J 7 Hz, 3H); TOF MS ES exact mass calculated for C 3 0
H
3 3
N
2 0 6 mlz =517.2339. Found: 517.2334.
IR (CHC1 3 cm 2965, 1738, 1454.
Anal. Calcd for C 30
H
32
N
2 0 6 C, 69.75; H, 6.24; N, 5.42.
Found: C, 69.73; H, 6.33; N, 5.25.
Exanple Preparation of (2-Ethyl-5-hydlroxy-4-isoxazol-5-ylphenoxy)propoxy] -2-propylphenoxy)benzoic acid.
WO 01/34580 PCT/US00/30942 -99- 000 COOMe N-n COO Me A. Preparation of 2-{3-[3-(5-benzyloxy-2-ethyl-4-isoxazol- 5-yl-phenoxy)propoxy]-2-propylphenoxy)benzoic acid methyl ester.
A mixture of 2-(3-{3-[5-benzyloxy-4-(3di me thyk rlnm r l r1tr1 2 t-h.y1 rlphe^ anvy rl ropo-r\ propylphenoxy)benzoic acid methyl ester (280 mg, 0.43 mmol), hydroxylamine hydrochloride (75 mg, 1.1 mmol), and water (1 mL) in methanol (4 mL) was heated at reflux for 2 h. The mixture was cooled to room temperature and diluted with diethyl ether and water. The organic layer was separated, washed with saturated sodium chloride solution, dried (sodium sulfate), filtered, and concentrated in vacuo.
Chromatography (silica gel, 10% ethyl acetate/90% hexane) of the residue provided 202 mg of the title compound as a white solid. H NMR (CDC13) 8 8.20 J 2 Hz, 1H), 7.88 (dd, J 9, 2 Hz, 1H), 7.79 1H), 7.40 7H), 7.08 (m, 2H), 6.68 J 8 Hz, 1H), 6.59 1H), 6.58 1H), 6.43 J 8 Hz, 1H), 5.15 2H), 4.21 J 6 Hz, 4H), 3.82 3H), 2.65 4H), 2.33 (quintet, J 6 Hz, 2H) 1.56 (hextet, J 8 Hz, 2H), 1.20 J 7 Hz. 3H), 0.90 J 7 Hz, 3H); TOF MS ES exact mass calculated 0.90 J 7 Hz, 3H); TOF MS ES exact mass calculated WO 01/34580 PCT/US00/30942 -100for C 38
H
40 N0 7 m/z 622.2805. Found: 622.2817. IR -1 (CHC1 3 cm 2964, 1720, 1461.
Anal. Calcd for C 38
H
39 N0 7 C, 73.41; H, 6.32; N, 2.25.
Found: C, 73.20; H, 6.34; N, 2.27.
N-
COOMe
N-
0
OH
COOMe B. Preparation of 2-(3-[3-(2-ethyl-5-hydroxy-4-isoxazol-5yl-phenoxy)propoxy]-2-propylphenoxy)benzoic acid methyl ester.
A solution of 2-{3-[3-(5-benzyloxy-2-ethyl-4-isoxazol-5-ylphenoxy)propoxy]-2-propylphenoxy}benzoic acid methyl ester (180 mg, 0.289 mmol) in ethanethiol (5 mL) was treated with boron trifluoride etherate (1.5 mL) at room temperature for 2 h, at which time an additional portion of boron trifluoride etherate (0.5 mL) was added and stirring resumed for an additional 1 h. The mixture was diluted with diethyl ether and water. The organic layer was separated, washed once with saturated sodium bicarbonate solution, once with saturated sodium chloride solution, dried (sodium sulfate), filtered, and concentrated in vacuo. Chromatography (silica gel, 15% ethyl acetate/85% hexane) of the residue provided WO 01/34580 WO 0134580PCTIUSOO/30942 -101- 94 mg of the title compound as a colorless oil. H NMR (CDC1 3 8 8.28 J 1 Hz, 1H), 7.88 (dd, J 8, 2 Hz, 1H) 7.38 J 8 Hz,l1H) 7.36 1H) 7.08 J 8 Hz, 1H), 7.05 Cd, J 8 Hz, 1H), 6.81 J 8 Hz, lH), 6.67 J 8 Hz, 1H), 6.50 1H) 6.45 1H) 6.43 J= 8 Hz, 1H), 4.20 (mn, 4H), 3.83 3H), 2.62 4H). 2.34 (quintet, J 6 Hz, 2H1), 1.54 (hextet, J 8 Hz, 2H), 1.18 J 8 Hz, 3H1), 0.90 Ct, J= 7 Hz, 3H); TOF MS ES exact mass calculated for C 31
H
34 N0 7 m/z 532.2335.
Found: 532.2335. IR (CHCl 3 cm 2964, 1715, 1601, 1461.
Anal. Calcd for C 31
H
33 N0 7 C, 70.04; H, 6.26; N, 2.63.
Found: C, 70.13; H, 6.35; N, 2.63.
N-b 9 9H COOMe
N-
0
OH
0" 0510 COOH C. Preparation of 2-(3-[3-(2-ethyl-5-hydroxy-4-iUoxazol-5yl-phenoxy)propoxy] -2-propylphenoxy)benzoic acid.
To a solution of 2-{3-[3-(2-ethyl-5-hydroxy-4-iSOXazol-5-ylphenoxy)propoxy] -2-propylphenoxy)benzoic acid methyl ester (94 mg, 0.18 rimnol) in methanol (3 mL) was added 1 M hydroxide solution (1 mL) and the resulting mixture warmed WO 01/34580 WO 0134580PCTUSOO/30942 -102at 60 OC for 3 h. The mixture was cooled to room temperature and concentrated in vacuo. The aqueous residue was diluted with water and the pH adjusted to The mixture was extracted three times with methylene chloride.
The combined organic extracts were dried (sodium sulfate), filtered, and concentrated in vacuo to provide 12 mg (13%) cf te tiic cmpcud acan 1 NMR (CDCl 3 8 8.26 1H), 8.20 (dd, J 8, 1 Hz, 1H), 7.49 J 6 Hz, 1H), 7.36 1H), 7.18 J 8 Hz, 1Hi), 7.15 J =8 Hz, 1H), 7.02 Cbs, 1H), 6.80 J 8 Hz, 1H), 6.69 J 8 Hz, 1H), 6.60 J 8 Hz, 1H), 6.50 1H1), 6.46 1H), 4.22 J 6 Hz, 2H), 4.19 J= 6 Hz, 2H); 2.57 Cm, 4H), 2.34 (quintet, J =6 Hz, 2H), 1.47 (hextet, J 8 Hz, 2H), 1.16 J 8 Hz, 3H), 0.85 J= 7 Hz, 3H); TOS MS ES exact mass calculated for C 30
H
32 N0 7 miz 518.2179. Found; 018.17I Anal. Calcd for C 3 0
H
3 1 N0 7 C, 69.62; H, 6.04; N, 2.71.
Found: C, 69.57; H, 6.15; N, 2.74.
Example 6 Preparation of (2-Ethyl-5-hydxoxy-4- (3R- [1,2,31 triazol-4-yl) phenoxyl propoxy) -2 -propylphenoxy)benzoic acid.
WO 01/34580 PCT/USOO/30942 -103- O- CI COOMe COOMe A. Preparation of 2-{3-[3-(5-benzyloxy-4-brono-2ethylphenoxy)propoxy]-2-propylphenoxy)-benzoic acid methyl ester.
A mixture of 5-benzyloxy-4-bromo-l-(3-chloropropoxy)-2ethylbenzene (1.19 g, 3.11 mmol), 2-(3-hydroxy-2propylphenoxy)benzoic acid methyl ester (0.89 g, 3.1 mmol), potassium carbonate (1.29 g, 9.34 mmol), potassium iodide (0.52 g, 3.1 mmol), and methyl sulfoxide (2 mL) in 2butanone (20 mL) was heated at reflux for 48 h. The mixture was cooled to room temperature, diluted with diethyl ether, and washed once with water. The organic layer was dried (sodium sulfate), filtered, and concentrated in vacuo.
Chromatography (silica gel, 6% ethyl acetate/94% hexane) of the residue provided 1.34 g of the title compound as a colorless oil. H NMR (CDC13) 6 7.91 (dd, J 8, 2 Hz, 1H), 7.50 J 7 Hz, 2H), 7.38 5H), 7.15 J 8 Hz, 1H), 7.10 J 8 Hz, 1H), 6.83 J 8 Hz, 1H), 6.71 J 8 Hz, 1H), 6.55 1H), 6.48 J 8 Hz, 1H), 5.16 2H), 4.21 J 6 Hz, 2H), 4.15 J 6 Hz, 2H), 3.83 3H), 2.68 J 8 Hz, 2H), 2.58 J 7 Hz, 2H), 2.31 (quintet, J 6 Hz, 2H), 1.58 (hextet, J 6 Hz, 2H), 1.17 J 7 Hz, 3H), 0.93 J 7 Hz, 3H).
WO 01/34580 PCT/USOO/30942 -104- Br COOMe 0o COOMe B. Preparation of 2-(3-[3-(5-benzyloxy-2-ethyl-4ethynylphenoxy)propoxy]-2-propyl-phenoxy}benzoic acid methyl ester.
A mixture of 2-{3-[3-(5-benzyloxy-4-bromo-2ethylphenoxy)propoxy]-2-propylphenoxy}-benzoic acid methyl ester (1.50 g, 2.37 mmol), tri-n-butylethynyltin (0.82 mL, 2.8 mmol), and tetrakis(triphenylphosphine)palladium (0) g, 0.95 mmol) in N,N-dimethylformamide (25 mL) was purged with argon and heated in a sealed tube at 120 oC for 24 h. The mixture was cooled to room temperature and filtered. The filtrate was diluted with ethyl acetate, washed four times with water, once with saturated sodium chloride solution, dried (sodium sulfate), filtered, and concentrated in vacuo. Chromatography (silica gel, ethyl acetate/90% hexane) of the residue provided 532 mg 1 of the title compound as a brown oil. H NMR (CDC1 3 8 7.88 (dd, J 8, 2 Hz, 1H), 7.79 1H), 7.20-7.50 (m, 6H), 7.10 J 8 Hz, 1H), 7.05 J 8 Hz, 1H), 6.80 J 8 Hz, 1H). 6.66 J 8 Hz 1H) 6.43 2H), 5.16 2H), 4.17 J 6 Hz, 2H), 4.11 J 6 Hz, 2H), 3.83 3H), 3.23 1H), 2.64 J 8 Hz, 2H), WO 01/34580 PCT/US00/30942 -105- 2.53 J 7 Hz, 2H), 2.27 (quintet, J 6 Hz, 2H), 1.53 2H), 1.13 J 7 Hz, 3H), 0.89 J 7 Hz, 3H); TOF MS ES exact mass calculated for C 37
H
39 0 6 m/z 579.2747. Found: 579.2739.
COOMe
H
COOMe C. Preparation of 2-(3-{3-[5-benzyloxy-2-ethyl-4-(3H- [1,2,3]triazol-4-yl)phenoxy]-propoxy)-2propylphenoxy)benzoic acid methyl ester.
A mixture of 2-{3-[3-(5-benzyloxy-2-ethyl-4ethynylphenoxy)propoxy] -2-propyl-phenoxy}benzoic acid methyl ester (517 mg, 0.893 mmol) and trimethylsilyl azide (3.0 mL, 18 mmol) was heated in toluene (20 mL) in a sealed tube at 130 oC for 120 h. The mixture was cooled to room temperature and concentrated in vacuo. Chromatography (silica gel, 10% ethyl acetate/90% hexane to 50% ethyl hexane) of the residue provided 347 mg (88% based upon recovered starting material) of the title 1 compound as a brown solid. H NMR (CDC1 3 6 8.10 (bs, 1H), 7.89 (dd, J 8, 2 Hz, 1H), 7.76 1H), 7.40 7H), 7.10 J 8 Hz, 1H), 7.05 J 8 Hz, 1H), 6.79 J 8 Hz, 1H), 6.67 J 8 Hz, 1H), 6.62 1H), 6.43 J WO 01/34580 PCT/US00/30942 -106- 8 Hz, 1H), 5.18 2H), 4.21 4H), 3.82 3H), 2.65 4H), 2.32 (quintet, J 6 Hz, 2H), 1.56 (hextet, J 8 Hz, 2H), 1.21 J 8 Hz, 3H), 0.90 J 7 Hz, 3H); TOF MS ES exact mass calculated for C 3 7
H
4 0
N
3 0 6 m/z -1 622.2917. Found: 622.2946. IR (CHC1 3 cm 3400, 1721, 1602, 1453.
Anal. Calcd for C 37
H
3 9
N
3 0 6 C, 71.48; H, 6.32; N, 6.76.
Found: C, 70.28; H, 6.07; N, 6.54.
H
N-N H .N-N OH I I^ N COOMe D. Preparation of 2-(3-{3-[2-ethyl-5-hydroxy-4-(3H- [1,2,3]triazol-4-yl)phenoxy]-propoxy)-2-propylphenoxy)benzoic acid methyl ester.
A solution of 2-(3-{3-[5-benzyloxy-2-ethyl-4-(3H- [1,2,3]triazol-4-yl)phenoxy]propoxy)-2-propylphenoxy)benzoic acid methyl ester (330 mg, 0.531 mmol) in ethanethiol (9 mL) was treated with boron trifluoride etherate (2.0 mL,16 mmol) for 1 h at room temperature and then with an additional portion of boron trifluoride etherate (1.0 mL) for 1 h. The mixture was diluted with diethyl ether and water. The organic layer was washed once with saturated sodium bicarbonate solution, once with saturated sodium chloride WO 01/34580 WO 0134580PCTUSOO/30942 -107solution, dried (sodium sulfate), filtered, and concentrated in vacuo. Chromatography (silica gel, 30% ethyl hexane to 50% ethyl acetate/50% hexane) of the residue provided 180 mg of the title compound as a brown solid. H NNR (CDCl 3 S 7.97 1H), 7.88 (dd, J 8, 2 Hz, 1H), 7.37 J 8 Hz, 1H), 7.31 1H), 7.10 J= 8 Hz, 1H), 7.05 J 8 Hz, lH), 6.81 J 8 Hz, lH), 6.67 J 8 Hz, 1H), 6.59 1H), 6.43 J =8 Hz, 1H), 4.20 (in, 4H), 3.83 3H), 2.63 (in, 4H), 2.34 (quintet, J 6 Hz, 2H), 1.55 (hextet, J 8 Hz, 2H), 1.19 J 8 Hz, 3H), 0.90 J 7 Hz, 3H); TOF MS ES exact mass calculated for C 3 0
H
34
N
3 0 6 m/z 532.2447.
-1 Found: 532.2466. IR (CHCl 3 cm 2964, 1718, 1453.
Anal. Calcd for C 30
H
33
N
3 0 6 C, 67.78; H, 6.26; N, 7.90.
Found: C, 66.80; H, 6.02; N, 7.53.
,NN H -0 N COOMe ,N-N HH
NN
COOH
E. Preparation of 2-(3-(3-[2-ethyl-5-hydroxy-4-(3H- ~~~1pooy ,y 2 propyiphenoxy) benzoic acid.
WO 01/34580 PCT/US00/30942 -108- A solution of 2-(3-{3-[2-ethyl-5-hydroxy-4-(3H- [1,2,3]triazol-4-yl)phenoxy]propoxy}-2-propylphenoxy)benzoic acid methyl ester (160 mg, 0.30 mmol) in methanol (5 mL) was treated 1 N lithium hydroxide solution (1.5 mL) at 60 oC for 3.5 h. The mixture was cooled to room temperature, diluted with water, and adjusted to -pH 4. The resulting mixture T~.r o-trt-rH thrpp times with methvlene chloride. The combined organic extracts were dried (sodium sulfate), filtered, and concentrated in vacuo to provide 134 mg (86%) 1 of the title compound as a tan solid. H NMR (DMSO-d) 6 14.98 (bs, 1H), 12.80 (bs, 1H), 10.02 (bs, 1H), 8.17 (bs, 1H), 7.77 (dd, J 7, 2 Hz, 1H), 7.60 (bs, 1H), 7.47 J 8 Hz, 1H), 7.18 J 8 Hz, 1H), 7.14 J 8 Hz, 1H), 6.82 J 8 Hz, 1H), 6.68 J 8 Hz, 1H), 6.57 (s, 1H), 6.35 J 8 Hz, 1H), 4.22 J 6 Hz, 2H), 4.15 J 6 Hz, 2H), 2.54 4H), 2.25 (quintet, J 6 Hz, 2H), 1.45 (hextet, J 8 Hz, 2H), 1.11 J 7 Hz, 3H), 0.81 J 7 Hz, 3H); TOF MS ES exact mass calculated for C 2 9
H
32
N
3 0 6 m/z 518.2291. Found: 518.2302.
-1 IR (CHC1 3 cm 2965, 1738, 1454.
Anal. Calcd for C 29
H
3 1
N
3 0 6 C, 67.30; H, 6.04; N, 8.12.
Found: C, 67.15; H, 5.98; N, 7.93.
Example 7 Preparation of 2-{3-[3-(2-Ethyl-5-hydroxy-4-pyrrol-1-ylphenoxy)propoxy]-2-propyl-phenoxy}benzoic acid methyl ester.
OH
OH
OH
I
WO 01/34580 PCT/US00/30942 -109- A. Preparation of 5-benzyloxy-2-ethyl-4-pyrrol-l-yl-phenol.
To a mixture of potassium nitrosodisulfonate (40.0 g, 149 mmol) and potassium hydrogen phosphate (10 g) in water (1.2 L) at room temperature was added a solution of 4ethylbenzene-1,3-diol (10.0 g, 2.37 mmol) and potassium hydrogen phosphate (10.5 g) in water (150 mL). The mixture was stirred for 15 min and adiit- t-n f n rT -13 Th aonlt-in, was extracted three times with diethyl ether. The organic layer was dried (sodium sulfate), filtered, and concentrated in vacuo. The residue was dissolved in acetonitrile (70 mL) and treated at room temperature with 65% 3-pyrroline (12 mL). The resulting mixture was stirred for 1 h and concentrated in vacuo, dissolved in ethyl acetate and hexane, and filtered down a short column of silica gel. The resulting solution was concentrated in vacuo. The residue was dissolved in N,N-dimethylformamide (10 mL) and treated with benzyl bromide (0.85 mL, 7.1 mmol) and potassium carbonate (960 mg, 6.9 mmol) at room temperature for 15 h.
The mixture was diluted with ethyl acetate, washed four times with water, once with saturated sodium chloride solution, dried (sodium sulfate), filtered, and concentrated in vacuo. Chromatography (silica gel, ethyl acetate/hexane gradient) of the residue provided 316 mg of the title compound. TOF MS ES exact mass calculated for C 19
H
20
NO
2 m/z 294.1494. Found: 294.1471.
B. Preparation of 1-[2-benzyloxy-4-(3-chloropropoxy)-5ethylphenyl]-1H-pyrrole.
WO 01/34580 WO 0134580PCTIUSOO/30942 -110- A mixture of 5-benzyloxy-2-ethyl-4-pyrrol-1-yl-phenol (316 mg, 1.08 mmol), potassium carbonate (223 mg, 1.62 mmol), and l-bromo-3-chloropropane (0.16 mL, 1.6 mmol) in N,Ndimethylforrnamide (5 mL) was stirred at room temperature for 18 h. The mixture was diluted with ethyl acetate and water, washed four times with water, once with saturated sodium chloride solution, dried (sodium sulfate), filtered, and concentrated in vacuo. Chromatography (silica gel, 5% ethyl acetate/95% hexane) of the residue provided 314 mg of the title compound as a colorless oil. TOF MS ES exact mass calculated for C 22
H
25 NC10 2 m/z 370.1574.
Found: 370.1548.
COOMe C. Preparation of 2-f 3-[3-(5-benzyloxy-2-sthyl-4-pyrrol-l- -la.sy acidnnn~ hnnr. -n nn ethyl ester.
WO 01/34580 PCT/US00/30942 -111- A mixture of 1-[2-benzyloxy-4-(3-chloropropoxy)-5ethylphenyl]-1H-pyrrole (310 mg, 0.85 mmol) and sodium iodide (140 mg, 0.94 mol) in 2-butanone (5 mL) was heated at reflux for 6 h. The mixture was cooled to room temperature, filtered, and concentrated in vacuo. The residue was dissolved in N,N-dimethylformamide (7 mL) and treated with mg, 0.85 mmol) and potassium carbonate (129 g, 93 mmol) at room temperature for 15 h. The mixture was diluted with ethyl acetate and water, washed four times with water, once with saturated sodium chloride solution, dried (sodium sulfate), filtered, and concentrated in vacuo.
Chromatography (silica gel, 5% ethyl acetate/95% hexane) of the residue provided 196 mg of the title compound as a colorless oil. H NMR (CDC13) 8 7.86 (dd, J 8, 2 Hz, 1H), 7.37 (dt, J 8, 2 Hz, 1H), 7.30 5H), 7.07 3H), 6.84 2H), 6.79 J 8 Hz, 1H), 6.65 J 8 Hz, 1H), 6.58 1H), 6.42 J 8 Hz, 1H), 6.29 2H), 4.92 (s, 2H), 4.17 J 6 Hz, 2H), 4.15 J 6 Hz, 2H), 3.83 3H), 2.65 J 8 Hz, 2H), 2.58 J 7 Hz, 2H), 2.30 (quintet, J 6 Hz, 2H), 1.55 (hextet, J 8 Hz, 2H), 1.16 J 7 Hz, 3H), 0.80 J 7 Hz, 3H); TOF MS ES exact mass calculated for C 39
H
42
NO
6 m/z 620.3012.
Found: 620.3021.
WO 01/34580 WO 0134580PCT/USOO/30942 -112- COOMe /~9H COOMe D. Preparation of (2-ethyl-5-hydroxy-4-pyrrol-1-ylphenoxy)propoxy] -2-propyl-phenoxy)benzoic acid methyl ester.
A solution of (5-benzyloxy-2-ethyl-4-pyrrol-l-ylphenoxy)propoxy] -2-propylphenoxy)benzoic acid methyl ester (195 mg, 0.315 mmol) in ethanethiol (5 mL) was treated with boron trifluoride etherate (1.3 mL, 9.5 mmol) at room temperature for 2.5 h. The mixture was diluted with diethyl ether and water. The organic layer was washed with saturated sodium bicarbonate solution, dried (sodium sulfate), filtered, and concentrated in vacuo.
Chromatography (silica gel, 10% ethyl acetate/90% hexane) of the residue provided 39 mg of the title compound as a colorless oil. H NMR (CDCl 3 8 7.89 J 8 Hz, 1H), 7.37 J 8 Hz, 1H), 7.07 2H), 6.98 1H), 6.68 (m, 3H), 6.65 J 8 Hz, 1H), 6.57 Cs, 1H1), 6.42 J 8 Hz, 1H), 6.35 (in, 2H), 5.04 Cbs, 1H), 4.19 (in, 2H), 3.83 (s, 3H), 2.64 J 8 Hz, 2H), 2.58 J 7 Hz, 2H), 2.32 (quintet, J 6 Hz, 2H) 1. 55 2H) 1.14 J 7 Hz, 3H), 0.90 Ct, J 7 Hz, 3H); TOF MS ES exact mass calculated for C 3 2
H
36 N0 6 miz 530.2543. Found: 530.2516.
WO 01/34580 PCTUSOO/30942 -113- Example 8 Preparation of 2-(3-(3-[4-(3-Bromo-[1,2,4]thiadiazol-5-yl)- -propoxy)-2-propyiphenoxy)benzoic acid.
Br COOMe COOMe A. Preparation of 2-(3-{3-[5-bezyloxy-2-ethyl-4-(4,4,5,5tetramethyl-[1,3,21dioxaborolan-2-yl)phenoxylpropoxy)-2propylphenoxy)benzoic acid methyl ester.
A mixture of 2-(3-[3-(5-benzyloxy-4-bromo-2ethyiphenoxy) propoxy -2-propyiphenoxy) -benzoic acid methyl ester (8.30 g, 13.1 mmol), triethylaxine (5.2 mL, 39 mmol), and PdCl 2 (dppf) (320 mg, 0.39 mmol) in de-oxygenated toluene (80 mL) was treated with a 1 M solution of 4,4,5,5tetramethyl-[1,3,2]dioxaborolane in tetrahydrofuran (20 nL, nmol) and heated at reflux for 6 h. The mixture was filtered down a short column of silica gel and the filtrate concentrated in vacuo. Chromatography (silica gel, ethyl acetate/65% hexane) of the residue provided a dark oil that was subjected to further chromatography (silica gel, hexane to 30% ethy,1 acetate/70% hevane) to fyiT0 770 f of the title compound. H NNR (CDC1 3 8 7.86 (dd, J 8, 2 WO 01/34580 PCT[USOO/30942 -114- Hz, 1H), 7.60 J 8 Hz, 2H), 7.47 1H), 7.34 3H), 7.24 J 8 Hz, 1H), 7.09 J 9 Hz, 1H), 7.04 J 9 Hz, 1H), 6.79 J 9 Hz, 1H), 6.66 J 9 Hz, 1H), 6.47 lH), 6.43 J 8 Hz, 1H), 5.07 2H), 4.18 (m, 4H), 3.81 3H), 2.64 J 8 Hz, 2H), 2.56 J 7 Hz, 2H), 2.30 (quintet, J 6 Hz, 2H), 1.53 (hextet, J 8 147.. 2W 1 I 19W1 1 1A Ii- .T 7 UJ., -2ul, 000 11- r 7 Hz, 3H); TOF MS ES exact mass calculated for C 4 1
H
53 NB0 8 (p Ni 4 mlz 698.3864. Found: 698.3889. IR (CHCl 3 -1 cm 2964, 1720, 1604, 1453.
Anal. Calcd for C 41
H
4 9 B0 8 C, 72.35; H, 7.26. Found: C, 72.30; H, 7.12.
COOMe Br N IKNJ 00j: COOMe B. Preparation of 2-(3-(3-5-benzyloxy-4-(3-bromo- [1,2,4]thiadiazol-5-yl)-2-ethyl-phenoxylpropoxy)-2propylphenoxy)benzoic acid methyl eater.
A mixture of 2-(3-(3-E5-benzyloxy-2-ethyl-4-(4,4,5,5tetramethyvl- 2i ioxaboral an- 2 -y 1) phenoxy] propoxy 1-2) propylphenoxy)benzoic acid methyl ester (310 mg, 0.46 mmol), WO 01/34580 PCT/US00/30942 -115- 3-bromo-5-chloro-1,2,4-thiadiazole (120 mg, 0.60 mmol), cesium carbonate (300 mg, 0.92 mmol), and PdCl 2 (dppf) mg, 0.024 mmol) in de-oxygenated toluene (10 mL) was heated at 100 oC for 15 h. The mixture was diluted with a solution of 35% ethyl acetate/65% hexane and filtered down a short column of silica gel. The filtrate was concentrated in vacuo. Chromatography (silica gel, hexane to 30% ethyl hexane) of the residue provided 232 mg of 1 the title compound. H NMR (CDC13) 6 8.13 1H), 7.87 (dd, J 8, 2 Hz, 1H), 7.44 2H), 7.37 4H), 7.08 (t, dJ 8, 1 Hz, 1H), 7.04 J 9 Hz, 1H), 6.78 J 9 Hz, 1H), 6.66 J 9 Hz, 1H), 6.55 1H), 6.43 J 8 Hz, 1H), 5.28 2H), 4.21 J 6 Hz, 2H), 4.19 J 6 Hz, 2H), 3.81 3H), 2.62 4H), 2.34 (quintet, J 6 Hz, 2H), 1.55 (hextet, J 8 Hz, 2H), 1.17 J 7 Hz, 3H), 0.88 J 7 Hzi 38); MS ES m/e 717, 719.
Br N 9V^ N. I I 000 COOMe Br -N H
N
S I
I
COOH
C. Preparation of 2-(3-(3-[4-(3-bromo-[1,2,4]thiadiazol-5yl)-2-ethyl-5-hydroxyphenoxy]propoxy)-2propylphenoxy)benzoic acid.
WO 01/34580 WO 0134580PCT/USOO/30942 -116- A solution of 2-(3-{3-[5-benzyloxy-4-(3-bromo- [l,2,4]thiadiazol-5-yl)-2-ethyl-phenoxy]propoxy)-2propylphenoxy)benzoic acid methyl ester (230 mg, 0.31 mmol) in ethanethiol (4 mL) was treated with boron trifluoride etherate (0.32 mL, 2.5 mmol) at room temperature for 6 h, at which time an additional portion of boron trifluoride t:L41eLaLte wati atdU -a cLL~U d L.L iiy cu.LLutI.. fLI.L 7 -1 JI reaction mixture was diluted with water, concentrated in vacuo, and extracted with diethyl ether. The residue was dissolved in methanol (5 mL) and treated with 1 N lithium hydroxide solution (2 mL) at 65 OC for 1 h. The mixture was concentrated in vacuo and the residue diluted with water and adjusted to -pH 3 with 1 N hydrochloric acid. The resulting precipitate was collected via vacuum filtration and dissolved in dilute aqueous base. Reverse phase chromatography (1:1 acetonitrile/water) provided 43 mg (23%) 1 of the title compound as a yellow solid. H NMR (DMSO-d 6 0 7.85 1H), 7.80 (dd, J 8, 2 Hz, 1H), 7.45 (in, 2H), 7.15 (in, 3H), 6.83 J 9 Hz, 1H), 6.80 J 9 Hz, 1H), 6.62 1H), 6.35 J 9 Hz, lH). 4.20 (in, 4H), 2.55 (mn, 4H), 2.27 (quintet, J 5 Hz, 2H), 1.44 (hextet, J 8 Hz, 2H), 1.13 J 7 Hz, 3H), 0.81 J 7 Hz, 3H); MS ES 1 m/e 551 (p+NH 4 IR (KBr, cm 2900, 1696, 1603, 1461.
Anal. Calcd for C 29
H
29 BrN 2
O
6 S: C, 56.77; H, 4.76; N, 4.56.
Found: C, 56.63; H, 4.72; N, 3.98.
Example 9 Preparation of (2-Ethyl-5-hydroxy-4-thiophen-2-ylphenoxy) propoxy] -2-propyl-phenoxy)benzoic acid sodium salt.
WO 01/34580 PCT/US00/30942 -117- A. Preparation of 2-(3-[3-(2-ethyl-5-hydroxy-4-thiophen-2yl-phenoxy)propoxy]-2-propylphenoxy}benzoic acid methyl ester.
A mixture of 2-(3-{3-[5-benzyloxy-2-ethyl-4-(4,4,5,5tetramethyl-[1,3,2]dioxaborolan-2-yl)phenoxy]propoxy}-2propylphenoxy)benzoic acid methyl ester (300 mg, 0.44 mmol), mg, 2.17 mmol), and PdCl 2 (dppf) (20 mg, 0.024 mmol) in deoxygenated toluene (10 mL) was heated at 105 OC for 66 h.
The mixture was cooled to room temperature and concentrated in vacuo. The residue was dissolved in methylene chloride and filtered down a short column of silica gel. The filtrate was concentrated in vacuo. Chromatography (silica gel, 30% ethyl acetate/70% hexane) of the residue provided an oil that was dissolved in ethanethiol (4 mL) and treated with boron trifluoride etherate (0.44 mL, 3.4 mmol) at room temperature for 3 h. The mixture was diluted with water and extracted with diethyl ether. The organic layer was dried (sodium sulfate), filtered, and concentrated in vacuo.
Chromatography (silica gel, hexane to 30% ethyl hexane) of the residue provided 120 mg of the title compound as a yellow film. H NMR (CDC13) 5 7.85 (dd, J 8, 2 Hz, 1H), 7.35 J 8 Hz, 1H), 7.15 J 7 Hz, 1H), 7.03-7.15 5H), 6.80 J 9 Hz, 1H), 6.66 J 9 Hz, 1H), 6.51 1H), 6.42 J 8 Hz, 1H), 5.44 (bs, 1H), 4.18 4H), 3.82 3H), 2.62 J 8 Hz, 2H), 2.58 J 7 Hz, 2H), 2.54 (quintet, J 6 Hz, 2H), 1.52 (hextet, J 8 Hz, 2H), 1.16 J 7 Hz, 3H), 0.90 J 7 Hz, 3H); MS ES m/e 545 (p 1).
WO 01/34580 PCT/US00/30942 -118- B. Preparation of 2-(3-[3-(2-ethyl-5-hydroxy-4-thiophen-2yl-phenoxy)propoxy]-2-propylphenoxy)benzoic acid sodium salt.
I OH UUUMe 00
OH
0 0 0 COONa A solution of 2-{3-[3-(2-ethyl-5-hydroxy-4-thiophen-2-ylphenoxy)propoxy]-2-propylphenoxy}benzoic acid methyl ester (120 mg, 0.22 mmol) in methanol (3 mL) was treated with 1 N lithium hydroxide solution (0.5 mL) at room temperature for 1 h and then with an additional portion of 1 N lithium hydroxide solution (0.75 mL) for 18 h. The mixture was heated at 50 oC then concentrated in vacuo. The residue was acidified with dilute hydrochloric acid and extracted with diethyl ether. The organic layer was washed once with water and concentrated in vacuo. The residue was diluted with 1 N sodium hydroxide solution (0.22 mL), diethyl ether, and toluene. The mixture was concentrated in vacuo, dissolved in methylene chloride, and concentrated in vacuo to provide 1 120 mg of the title compound as a green film. H NMR (DMSO-d 6 8 7.71 J 8 Hz, 1H), 7.42 2H), 7.31 (m, 2H), 7.10 2H), 6.99 1H), 6.76 J 7 Hz, 2H), 6.52 1H), 6.30 J 8 Hz, 1H), 4.16 J 7 Hz, 2H), 4.07 J 7 Hz. 2H), 2.50 4H), 2.20 2H); 1.40 2H), 1.06 J 8 Hz, 3H), 0.77 J 7 Hz, WO 01/34580 PCTUSOO/30942 -119- -1 3H); MS ES m/e 533 (p 1 Na IR (CHC1 3 cm 2900, 1738, 1604, 1454.
Example Preparation of (2-Ethyl-5-hydroxy-4-(l-methyl-1Hpyrazol-4-yl) -phenoxy] propoxy) -2-propylphenoxy)benzoic acid.
N-N N-N
H
A. Preparation of 4-iodo-l-methylpyrazole (Known compound: RN 39806-90-1).
To a solution of 4-iodopyrazole (1.3 g, 6.8 mmol) in dioxane mL) was added iodomethane (0.42 mL, 6.8 mmol) and the resulting mixture stirred at room temperature for 96 h. The rixture was concentrated in vacuo and the residue mixed with methylene chloride and filtered. The filtrate was concentrated in vacuo to provide 1.35 g of the title compound as a colorless oil. H NMR (CDCl 3 8 7.47 1H), 7.38 1H), 3.90 3H).
B. Preparation of 2-(3-(3-[5-benzyloxy-2-ethyl-4-(l-methyl- 1H-pyazol-4-yl)phenoxyl-propoxy)-2-propylphenoxy)benzoia acid methyl ester.
A mixture of 2-(3-(3-[5-benzyloxy-2-ethyl-4-(4,4,5,5tetramethyl-[1,3,2]dioxaborolan-2-yl)phenoxylpropoxy}-2propylphenoxy)benzoic acid methyl ester (1.00 g, 1.47 mmol), 4-iodo-l-methylpyrazole (450 mg, 2.16 mmol), cesium carbonate (1.20 g, 3.62 mmol), and PdC1 2 (dppf) (72 mg, 0.088 mmol) in de-oxygenated toluene (35 iL) was heated at 100
O
C
for 24 h. Additional portions of 4-iodo-1-methylpyrazole WO 01/34580 WO 0134580PCTIUSOO/30942 -120mg) and PdCl 2 (dppf) (-30 mg) were added and heating continued at 100 0 C for 40 h. The mixture was cooled to room temperature, concentrated in vacuo, diluted with methylene chloride, and filtered down a short plug of silica gel. The filtrate was concentrated in vacuo.
Chromatography (silica gel, 35% ethyl acetate/65% hexane to ethyl acecate/35% hexane) of tne residue provided 710 MY~ of the title compound. H NMR (CDCl 3 8 7.86 (dd, J= 8, 2 Hz, 1H), 7.80 1H), 7.69 1H), 7.37 6H), 7.28 1H), 7.09 J 9 Hz, 1H), 7.04 J 9 Hz, 1H), 6.78 J 9 Hz, 1H), 6.67 J 9 Hz, 1H), 6.56 (s, 1H), 6.42 J 8 Hz, 1H) 5.08 2H), 4.18 Ct, J 6 Hz, 2H), 4.15 J 6 Hz, 2H), 3.85 3H), 3.81 Cs, 3H), 2.63 J =8 Hz, 2H), 2.59 J 7 Hz, 2H), 2.30 (quintet, J =6 Hz, 2H), 1.55 Chextet, J 8 Hz, 2H), 1.23 J =7 Hz, 3H), 0.89 Ct, J 7 Hz, 3H).
-NP
COO Me
COOH
C. Preparation of 2-(3-(3-[2-ethyl-5-hydroxy-4-(l-mothyl- 1H-pyrazol-4-yl) -phenoxy] propoxy) -2-propyiphenoxy) benzoic acid.
WO 01/34580 PCT/US00/30942 -121- A solution of 2-(3-{3-[5-benzyloxy-2-ethyl-4-(1-methyl-1Hpyrazol-4-yl)phenoxy]propoxy}-2-propylphenoxy)benzoic acid methyl ester (710 mg, 1.12 mmol) in ethanethiol (5 mL) was treated with boron trifluoride etherate (1.42 mL, 11.2 mmol) at room temperature for 20 h. The reaction mixture was diluted with water, concentrated in vacuo, and extracted with diethvl ether. The oraanic layer was dried (marnPRim sulfate), filtered, and concentrated in vacuo. The residue was triturated twice with hexane and the residue dissolved in methanol (5 mL). This solution was treated with 1 N lithium hydroxide solution (5 mL) at -95 oC for 2 h. The mixture was concentrated in vacuo and the residue diluted with water, washed twice with diethyl ether, and the aqueous layer acidified with 1 N hydrochloric acid. The resulting solution was extracted with diethyl ether. The organic layer was dried (magnesium sulfate), filtered, and concentrated in vacuo. Chromatography (silica gel, methylene chloride) provided 338 mg of the title compound as a tan foam. H NMR (DMSO-d 6 8 12.85 (bs, 1H), 9.50 (bs, 1H), 7.98 1H), 7.78 2H), 7.48 (dt, J 8, 2 Hz, 1H), 7.44 1H), 7.18 J 8 Hz, 1H), 7.13 J 9 Hz, 1H), 6.79 J 9 Hz, 1H), 6.77 J 9 Hz, 1H), 6.53 1H), 6.35 J 9 Hz, 1H), 4.20 J 6 Hz, 2H), 4.08 J 6 Hz, 2H), 3.85 3H), 2.50 (m, 4H), 2.24 (quintet, J 5 Hz, 2H), 1.45 (hextet, J 8 Hz, 2H), 1.09 J 7 Hz, 3H), 0.82 J 7 Hz, 3H); MS ES -1 m/e 531 IR (KBr, cm 2961, 1697, 1602, 1460, 1222.
Anal. Calcd for C 31
H
34
N
2 0 6 C, 70.17; H, 6.46; N, 5.28.
Found: C, 69.27; H, 6.08; N, 4.63.
WO 01/34580 PCTIUSOO/30942 -122- Example 11 Preparation of 2-(3-[3-(2-Ethl-5-hydroxy-4-thiazol-2-ylphenoxy)propoxy]-2-propyl-phenoxy)benzoic acid.
O-B
N~
S Br COOMe S N 0 O COOMe A. Preparation of [3-(5-benzyloxy-2-ethyl-4-thiazol-2yl-phenoxy)propoxyl-2-propylphenoxybenzoic acid methyl eater.
A mixture of 2-(3-(3-t5-benzyloxy-2-ethyl-4-(4,4,5,5tetramethyl-[1,3,2]dioxaborolan-2-yl)phenoxy)propoxy)-2propylphenoxy)benzoic acid methyl ester (960 mg, 1.41 mmol), 2-bromothiazole (0.25 mL, 2.8 nmol), cesium carbonate (1.15 g, 3.52 mmol), and PdC1 2 (dppf) (35 mg, 0.040 mmol) in deoxygenated toluene (35 mL) was heated at 60 0 C for 16 h then at 100 0 C for 7 h. Additional portions of 2-bromothiazole (0.13 mL) and PdCl 2 (dppf) (-30 mg) were added and heating continued at 100 0 C for 72 h. The mixture was cooled to room temperature, concentrated in vacuo, diluted with methylene chloride, and filtered down a short plug of silica gel. The filtrate was concentrated in vacuo.
Chromatography (silica gel, hexane to 35% ethyl WO 01/34580 WO 0134580PCTUSOO/30942 -123hexane) of the residue provided 282 mg of the title compound.
Hz, 1H) 7 .8 7.35 (in, 4H) 1H) 7.04 (c J 9 Hz 5.24 2H) (quintet, J J =7 Hi H NMR (CDCl 3 8 8.20 1H) 7.86 (cid, J 8, 1 ~2 J =3 Hz, 1H) 7.49 (di, J 7 Hz, 2H) 7.23 J 3 Hz, 1H), 7.09 J 9 Hz, IJ 9 Hz, 1H), 6.78 Cd, J 9 Hz, 1H), 6.65 1, H) 6.57 lH) 6.42 J 8 Hz, 1H) 4.17 (in, 4H), 3.81 3H), 2.63 4H), 2.33 =6 Hz, 2H), 1.55 (hextet, J 8 Hz, 2H), 1.19 0.88 J 7 Hz, 3H).
~NH
I 0 NCOOMe B. Preparation of 2-(3-[3-(2-ethyl-5-hydroxy-4-thiazol-2- Yl-phenoxy)propoxyj -2-propylphenoxy)benzoic acid =ethyl ester.
A solution of 2-{3-[3-(5-benzyloxy-2-ethyl-4-thiazol-2-ylphenoxy)propoxy] -2-propylphenoxylbenzoic acid methyl ester (282 mng, 0.442 inmol) in ethanethiol (3 mL) was treated with boron trifluoride etherate (0.56 mL, 4.4 mmol) at room temperature for 3 h. The reaction mixture was diluted with water, concentrated in vacuo, and extracted with diethyl ether. The orgaiiic layer was dried (magnesium sulfate), filtered, and concentrated in vacuo. Chromatography (silica WO 01/34580 PCT/US00/30942 -124gel, ethyl acetate/hexane) provided 107 mg of the title compound. H NMR (CDC1 3 8 7.88 (dd, J 8, 2 Hz, 1H), 7.80 J 4 Hz, 1H), 7.35 (dt, J 8, 2 Hz, 1H), 7.28 J 4 Hz, 1H), 7.24 1H), 7.09 (dt, J 9, 2 Hz, 1H), 7.05 J 9 Hz, 1H), 6.79 J 9 Hz, 1H), 6.66 J 9 Hz, 1H), 6.61 1H), 6.42 J 9 Hz, 1H), 4.24 J 6 Hz, 2H), 4.18 J 6 Hz, 2H), 3.81 (s, 3H), 2.63 J 7 Hz, 2H), 2.58 J 7 Hz, 2H), 2.34 (quintet, J 6 Hz, 2H), 1.52 (hextet, J 8 Hz, 2H), 1.17 J 7 Hz, 3H), 0.88 J 7 Hz, 3H); MS ES m/e 548 N H COOMe CN H
COOH
C. Preparation of 2-{3-[3-(2-ethyl-5-hydroxy-4-thiazol-2yl-phenoxy)propoxy]-2-propylphenoxy}benzoic acid.
2-{3-[3-(2-Ethyl-5-hydroxy-4-thiazol-2-yl-phenoxy)propoxy]- 2-propylphenoxy}benzoic acid methyl ester (107 mg, 0.196 mmol) was dissolved in a 1:1 solution of methanol/dioxane (3 mL) and treated with 1 N lithium hydroxide solution (1 mL) at 60 oC for 2 h. The mixture was concentrated in vacuo and the residue diluted with water, washed twice with diethyl ether, and the aqueous layer acidified with 1 N hydrochloric WO 01/34580 WO 0134580PCTIUSOO/30942 -125acid. The resulting solution was extracted twice with methylene chloride and the combined organic layers dried (magnesium sulfate), filtered, and concentrated in vacuo.
Trituration (hexane) of the residue provided 72 mg of 1 the title compound as a tan powder. H NMR (CDCl 3 8 8.22 (dd, j 8, 2 Hz, 1H), 7.70 J 4 Hz, 1H), 7.41 Cdt, J 8, 2 Hz, 1H) 7.35 1H), 7.18 Cm, 3H), 6.82 J 9 Hz, 1H), 6.69 J 9 Hz, 1H), 6.62 Cd, j 9 Hz, 1H), 6.55 18), 4.22 J 6 Hz, 28), 4.21 J 6 Hz, 2H), 2.57 (in, 48), 2.35 (quintet, J =6 Hz, 28), 1.49 (hextet, J -8 Hz, 2H), 1.18 Ct, J 7 Hz, 3H), 0.86 J 7 Hz, 38); -1 MS ES m/e 534 IR (KBr, cm 2957, 1695, 1599, 1457.
Anal. Calcd for C 30
H
31 N0 6 S: C, 67.52; H, 5.86; N, 2.62.
Found: C, 67.44; H, 5.95; N, 2.55.
Ekample 12 Preparation of 2-(3-(3-[4-(3,5-Dimethylisoxazol-4-y1)-2propoxy} -2-propylphenoxy)benzoic acid sodium salt.
WO 01/34580 PCT/USOO/30942 -126- 0 I I I I 0- CCOOMe 0
OH
COONa A mixture of 2--(3-{3-[5-benzyloxy-2-ethyl-4-(44,45,5tetramethyl-[1,3,2]dioxaborolan-2-yl)phenoxy]propoxy)-2propylphenoxy)benzoic acid methyl ester (305 mg, 0.448 mmol), 3,5-dimethyl-4-iodoisoxazole (110 mg, 0.493 mmol), cesium carbonate (293 mg, 0.899 mmol), and PdCl 2 (dppf) mg, 0.018 mmol) in de-oxygenated toluene (10 mL) was heated at 95 oC for 10 h. Additional portions of 3,5-dimethyl-4iodoisoxazole (110 mg), cesium carbonate (260 mg), and PdCl 2 (dppf) (-15 mg) were added and heating continued at 110 oC for 20 h. The mixture was cooled to room temperature, concentrated in vacuo, diluted with methylene chloride, and filtered down a short plug of silica gel with 20% ethyl acetate/80% hexane. The filtrate was concentrated in vacuo.
The resulting colorless oil was dissolved in methylene chloride (4 mL), cooled to 0 OC, and treated with iodotrimethylsilane (0.40 mL, 2.7 mmol). The resulting WO 01/34580 WO 0134580PCTIUSOO/30942 -127mixture was allowed to warm to room temperature and stirred for 18 h. An additional portion of iodotrimethylsilane (0.70 mL) was added and stirring continued for 72 h. The mixture was poured into dilute sodium thiosulfate solution.
The organic layer was separated, washed with water, dried (sodium sulfate), filtered, and concentrated in vacuo. The resultina foam was dissoluv~d in a 1-1 miwtiiv-, if tetrahydrofuran/l N hydrochloric acid (5 mL) and stirred at room temperature for 18 h. The mixture was concentrated in vacuo and treated with 1 equivalent 1 N sodium hydroxide solution in ether. The resulting mixture was concentrated in vacuo to provide 59 mg of the title compound as an off-white solid. H NMR (DMSO-d 6 5 7.40 (dd, J 9, 2 Hz, 1H), 7.13 (dt, J 2 Hz, 1H), 6.97 (in, 2H), 6.79 1H), 6.68 J 9 Hz, 1H), 6.65 J 9 Hz, 1H), 6.60 (s, 1Hi), 6.21 J 8 Hz, 1H), 4.19 J 6 Hz, 2H), 4.01 J 6 Hz, 2H), 2.66 J Hz, 2H), 2.48 J 8 Hz, 2H), 2.24 3H), 2.17 (quintet, J 6 Hz, 2H), 2.07 3 1.49 (hextet, J 8 Hz, 2H), 1.07 J 7 Hz, 3H), 0.85 J 7 Hz, 3H); TOF MS ES exact mass calculated for C 32
H
36 N0 7 m/z 546.2492. Found: -1 546.2514; IR (KBr, cm 3400, 1605, 1460.
Exanp1e 13 Preparation of 2-(3-[3-(2-Ethyl-4-furan-2-yl-5hydroxyphenoxy)propoxcy]-2-propylphenoxy)-benzoic acid sodium salt.
WO 01/34580 PCT/US00/30942 -128- Br COOMe nu Br COOMe A. Preparation of 2-(3-[3-(4-bromo-2-ethyl-5hydroxyphenoxy)propoxy]-2-propylphenoxy) benzoic acid methyl ester.
A solution of 2-{3-[3-(5-benzyloxy-4-bromo-2thylphenoxy) propoxy]-2-propylphcnoxy) -benzoic acid methyl ester (2.50 g, 3.95 mmol) in methylene chloride (40 mL) was cooled to -70 oC and treated with boron tribromide (0.25 mL, 2.6 mmol). After 25 min the mixture was poured into cold water and the resulting mixture extracted with methylene chloride. The combined organic extracts were washed once with water, once with saturated sodium chloride solution, dried (sodium sulfate), filtered, and concentrated in vacuo to provide 1.1 g of the title compound as a pale 1 yellow oil. H NMR (CDC1 3 8 7.89 J 9 Hz, 1H), 7.38 J 8 Hz, 1H), 7.18 (s 1H), 7.12 J 9 Hz, 1H), 7.08 J 2 Hz, 1H), 6.81 J 9 Hz, 1H), 6.68 J 9 Hz, 1H), 6.56 1H), 6.46 J 9 Hz, 1H), 5.40 1H), 4.18 J 6 Hz, 2H), 4.11 J 6 Hz, 2H), 3.84 (s, 3H), 2.65 J 8 Hz, 2H), 2.54 J 7 Hz, 2H), 2.32 (quintet, J 6 Hz, 2H), 1.54 (hextet, J 8 Hz, 2H), 1.13 WO 01/34580 PCT/US00/30942 -129- J 7 Hz, 3H), 0.89 J 7 Hz, 3H); MS ES m/z 541 (M 543 (M H 2).
Br O 0O0 O
TBS
COOMe B. Preparation of 2-(3-(3-[4-bromo-5-(tertbutyldimethylsilanyloxy) -2-ethylphenoxy] -propozxy)-2propylphenoxy)benzoic acid methyl ester.
A solution of 2-(3-[3-(4-bromo-2-ethyl-5hydroxyphenoxy)propoxy]-2-propylphenoxy}benzoic acid methyl ester (1.00 g, 1.84 mmol) in methylene chloride (20 mL) was treated with imidazole (0.19 g, 2.8 mmol) and tertbutyldimethylsilyl chloride (0.388 g, 2.57 mmol) at room temperature for 2 h. The mixture was poured into water and the organic layer separated, washed once with water, once with saturated sodium chloride solution, filtered through a short pad of silica gel, and concentrated in vacuo to provide 1.1 g of the title compound as a colorless oil. H NMR (CDC1 3 6 7.88 J 9 Hz, 1H), 7.38 J 8 Hz, 1H), 7.22 (s 1H), 7.12 J 9 Hz, 1H), 7.08 J 2 Hz, 1H), 6.80 J 9 Hz, 1H), 6.69 J 9 Hz, 1H), 6.45 J 9 Hz, 1H), 6.40 1H), 4.20 J 6 Hz, 2H), 4.11 J 6 Hz, 2H), 3.83 3H), 2.64 J 8 Hz, 2H), 2.54 J 7 Hz, 2H), 2.32 (quintet, J 6 Hz, WO 01/34580 WO 0134580PCT[USOO/30942 -130- 2H), 1.54 (hextet, J 8 Hz, 2H), 1.13 J 7 Hz, 3H), 1.03 9H), 0.89 J 7 Hz, 3H), 0.23 6H).
Br COOMe
H
COOMe C. Preparation of [3-(2-ethyl-4-furan-2-yl-5hydroxyphenoxy)propoxyj -2-propyl-phenoxy)benzoic acid methyl eater.
A mixture of 2-(3-(3-(4-bromo-5-(tertbutyldimethylsilanyloxy) -2-ethyiphenoxy] propoxy) -2propylphenoxy)benzoic acid methyl ester (1.05 g, 1.60 mmol), furan-2-boronic acid (0.358 g, 3.20 nmol), tetrakis(triphenylphosphine)palladium(0) (0.185 g, 0.160 mmol), and 2 M4 aqueous sodium carbonate solution (8 mL) in tetrahydrofuran (20 niL) was heated at ref lux for 18 h. The mixture was cooled to room temperature, diluted with water, and extracted with ethyl acetate. The organic layer was separated, washed once with water, once with saturated sodium chloride solution, dried (sodium sulfate), filtered, and concentrated in vacuo. Chromatography (silica gel, ethyl acetate/90% hexane) of the residue provided 0.8 g 1 of th comou~ as a1ools JL. H N% (CDCl1 3 8 7. 90 J 9 Hz, 1H) 7. 48 1H) 7. 38 J WO 01/34580 PCT/US00/30942 -131- 8 Hz, 1H), 7.21 (s 1H), 7.13 1H), 7.10 J 9 Hz, 1H), 7.07 J 2 Hz, 1H), 6.81 J 9 Hz, 1H), 6.69 J 9 Hz, 1H), 6.52 3H), 6.44 J 9 Hz, 1H), 4.20 4H), 3.83 3H), 2.67 J 8 Hz, 2H), 2.59 (q, J 7 Hz, 2H), 2.32 (quintet, J 6 Hz, 2H), 1.55 (hextet, J 8 Hz, 2H), 1.18 J 7 Hz, 3H), 0.91 J 7 Hz, 3H) S 5 i/z 583 (t E A- Anal. Calcd for C 32
H
34 0 7 C, 72.43; H, 6.46. Found: C, 72.21; H, 6.15.
H
00 COOMe O 'O O COONa D. Preparation of 2-(3-[3-(2-ethyl-4-furan-2-yl-5hydroxyphenoxy)propoxy] -2-propylphenoxy}benzoic acid sodium salt.
2-{3-[3-(2-Ethyl-4-furan-2-yl-5-hydroxyphenoxy)propoxy]-2propylphenoxy}benzoic acid methyl ester (250 mg, 0.47 mmol) was dissolved in tetrahydrofuran (4 mL) and treated with 1 N lithium hydroxide solution (2 mL) at 50 OC for 16 h. The mixture was concentrated in vacuo and the residue diluted with water and extracted twice with ethyl acetate. The combined organic extracts were washed once with water, once with saturated sodium chloride solution, dried (sodium WO 01/34580 WO 0134580PCT[USOO/30942 -132sulfate), filtered, and concentrated in vacuo. The residue was dissolved in ethyl acetate and shaken with 1 N hydrochloric acid. The organic layer was dried (sodium sulfate), filtered, and concentrated in vacuo. The residue was dissolved in diethyl ether and treated with 1 N aqueous sodium hydroxide solution (0.32 mL). The mixture was diethyl ether, chloroform, and diethyl ether and dried to provide 168 mg of the title product as a cream solid.
H NMR (DMSO-d 6 8 7.56 1H) 7.44 J 8 Hz, 1H) 7.35 1H), 7.13 (in, 1H), 6.97 (mn, 2H), 6.77 J =2 Hz, 1H), 6.65 (in, 4H), 6.48 J 2 Hz, 1H), 6.24 J =9 Hz, 1H), 4.15 J 6 Hz, 2H), 3.96 J 6 Hz, 2H), 2.66 J 8 Hz, 2H), 2.42 J 7 Hz, 2H), 2.13 (quintet, J =6 Hz, 2H), 1.48 (hextet, J 8 Hz, 2H), 1.09 J 7 Hz, 3H), 0.84 J =7 Hz, 3H); TOF MS ES exact mass calculated for C 31
H
33 0 7 m/z 517.2226.
Found: 517.2230. IR (KBr, cm )3400, 2961, 1599, 1460.
Example 14 Preparation of (2-Ethyl-5-hydxoxy-4-furan-3yl Iphenoxy] propoxy) -2 -propyiphenoxy) benzoic acid.
TBS
Br 0 N COO Me OaH 0COO~ WO 01/34580 WO 0134580PCTJUSOO/30942 -133- A. Preparation of 2-(3-[3-(2-ethyl-4-furan-3-yl-5hydroxyphenoxy) propoxy] -2 -propyl -phenoxy)benzoic acid methyl ester.
A mixture of 2-(3-{3-(4-bromo-5-(tertbutyldimethylsilanyloxy) -2-ethyiphenoxy] propoxy) -2propyiphenoxy)benzoic acid mecilyl e5LteL (2.13 1;LU..J furan-3-boronic acid (0.722 g, 6.45 mmol), tetrakis(triphenylphosphine)palladium(0) (0.37 g, 0.32 mmol), and 2 M aqueous sodium carbonate solution (16 mL) in tetrahydrofuran (30 mL) was heated at ref lux for 48 h. The mixture was cooled to room temperature, diluted with water, and extracted with ethyl acetate. The organic layer was separated, washed once with water, once with saturated sodium chloride solution, dried (sodium sulfate), filtered, and concentrated in vacuo. Chromatography (silica gel, ethyl acetate/85% hexane) of the residue providedA 0.29 g of the title compound as a yellow oil. TOF MS ES exact mass calculated for C 32
H
35 0 7 m/z 531.2383.
Found: 531.2396.
0
H
COOMe WO 01/34580 PCT/US00/30942 -134- B. Preparation of 2-(3-[3-(2-ethyl-4-furan-3-yl-5hydroxyphenoxy)propoxy]-2-propylphenoxy}benzoic acid sodium salt.
2-{3-(3-(2-Ethyl-4-furan-3-yl-5-hydroxyphenoxy)propoxy]-2propylphenoxy}benzoic acid methyl ester (170 mg, 0.32 mmol) was dissolved in tetrahydrofuran (4 mL) and methanol (1 mL) oC for 2 h. The mixture was concentrated in vacuo and the residue acidified with hydrochloric acid and the resulting mixture extracted twice with ethyl acetate. The combined organic extracts were washed once with water, once with saturated sodium chloride solution, dried (sodium sulfate), filtered, and concentrated in vacuo. Chromatography (silica gel, 2% methanol/98% chloroform) of the residue gave 45 mg of material that was again submitted to chromatography (silica gel, 1% methanol/99% chloroform) to provide 25 mg of the title compound as an oil.
TOF MS ES exact mass calculated for C 31
H
33 0 7 m/z 517.226. Found: 517.2230.
Example Preparation of .2-(3-{3-[2-Ethyl-5-hydroxy-4- (tetrahydrofuran-3-yl)phenoxy]propoxy)- 2propylphenoxy)benzoic acid sodium salt hemihydrate.
WO 01/34580 PCT/US00/30942 -135- Br-- S COOMe I I COOMe A. Preparation of 2-{3-[3-(5-benzyloxy-2-ethyl-4-furan-3yl-phenoxy)propoxy]-2-propylphenoxy)benzoic acid methyl ester.
A mixture of 2-{3-[3-(5-benzyloxy-4-bromo-2ethylphenoxy)propoxy]-2-propylphenoxy}-benzoic acid methyl ester (3.00 g, 4.73 mmol), furan-3-boronic acid (1.06 g, 9.47 mmol), tetrakis(triphenylphosphine)palladium(0) (0.54 g, 0.47 mmol), and 2 M aqueous sodium carbonate solution mL) in tetrahydrofuran (40 mL) was heated at 100 oC for 48 h. The mixture was cooled to room temperature, diluted with water, and extracted with ethyl acetate. The organic layer was separated, washed once with water, once with saturated sodium chloride solution, dried (sodium sulfate), filtered, and concentrated in vacuo. Chromatography (silica gel, ethyl acetate/90% hexane) of the residue provided 1.9 g 1 of the title compound as a yellow oil. H NMR (CDC1 3 6 7.88 (dd, J 8, 2 Hz, 1H), 7.87 1H), 7.40 7H), 7.26 (s 1H), 7.05 2H), 6.80 J 9 Hz, 1H), 6.76 (d, J 2 Hz, 1H), 6.67 J 9 Hz, 1H), 6.60 1H), 6.43 J 9 HK., 1H). 5.11 2H), 4.18 4H), 3.83 3H), 2.66 J 8 Hz, 2H), 2.62 J 7 Hz, 2H), 2.30 (quintet, J 6 Hz, 2H), 1.57 (hextet, J 8 Hz, 2H), 1.20 WO 01/34580 PCTUSO/30942 -136- J 7 Hz, 3H), 0.92 J 7 Hz, 3H); MS ES m/z 621 -1 (p IR (CHC1 3 cm 3000, 1727, 1603, 1461.
COOMe 0 H COOMe B. Preparation of 2-(3-(3-(2-ethyl-5-hydroxy-4- (tetrahydrofuran-3-yl)phenoxy]-propoxy)-2propylphenoxy)benzoic acid methyl ester.
A solution of 2-{3-[3-(5-benzyloxy-2-ethyl-4-furan-3-ylphenoxy)propoxy]-2-propylphenoxy)benzoic acid methyl ester (1.8 g, 2.9 mmol) in ethyl acetate (40 mL) was treated with palladium-on-carbon (0.39 g) and hydrogenated at 48 psi and 45 OC for 72 h. The mixture was cooled to room
TM
temperature, filtered through Celite and the filtrate concentrated in vacuo to provide 1.2 g of the title compound as a colorless oil. H NMR (CDC1 3 6 7.88 (dd, J 8, 2 Hz, 1H), 7.57 (dt, J 8, 2 Hz, 1H), 7.09 J 9 Hz, 1H), 7.04 J 9 Hz, 1H), 6.81 J 9 Hz, 1H), 6.80 1H), 6.67 J 9 Hz, 1H), 6.44 J 9 Hz, 1H), 6.43 1H), 4.19 3H), 4.10 2H), 4.02 (dd, J 12, 3 Hf, 1H, 3.00 1dd, J 12, 8 Hz, 1H), 3.84 3H), 3.73 J 9 Hz, 1H), 3.45 1H), 2.64 J 8 Hz, 2H), WO 01/34580 PCT/US00/30942 -137- 2.53 J 7 Hz, 2H), 2.38 1H), 2.28 (quintet, J 6 Hz, 2H), 1.99 1H), 1.55 (hextet, J 8 Hz, 2H), 1.15 (t, J 7 Hz, 3H), 0.90 J 7 Hz, 3H); MS ES m/z 593 (p -1
CH
3 COO IR (CHC1 3 cm 2963, 1719, 1589, 1461.
Anal. Calcd for C 32
H
38 0 7 C, 71.89; H, 7.16. Found: C, 71.41; H, 7.06.
0 OH 0
H
S COOMe 0
H
COONa C. Preparation of 2- (3-3-[2-ethyl-5-hydroxy-4- (tetrahydrofuran-3-yl) phenoxy]-propoxy)-2propylphenoxy)benzoic acid sodium salt hemihydrate.
A solution of 2-(3-(3-[2-ethyl-5-hydroxy-4-(tetrahydrofuran- 3-yl)phenoxy]propoxy}-2-propylphenoxy)benzoic acid methyl ester (0.92 g, 1.7 mmol) in tetrahydrofuran (10 mL) and methanol (5 mL) was treated with 1 M aqueous lithium hydroxide solution (10 mL) at 55 oC for 2 h. The mixture was allowed to cool to room temperature and stirred for an additional 18 h. The mixture was concentrated in vacuo and the remaining aqueous mixture was washed once with diethyl ether. The aqueous layer was acidified with concentrated hydrochloric acid and the resulting solution extracted with ethyl acetate. The ethyl acetate layer was washed once with WO 01/34580 WO 0134580PCTIUSOO/30942 -138water, once with saturated sodium chloride solution, dried (sodium sulfate), filtered, and concentrated in vacuo. The resulting colorless oil was dissolved in diethyl ether and treated with 1 N aqueous sodium hydroxide solution (1.72 ML). The resulting biphasic mixture was diluted with chloroform and concentrated in vacuo. Diethyl ether was ade an, t-he~m~Iir e-nnr.PntratRd in vacuo. The resulting white foam was dried in vacuo at room temperature for 60 h to provide 0.78 g of the title compound: mp 67-71 0
C.
H NMR (DMSO-d 6 8 7.62 (dd, J 8, 2 Hz, 1H) 7.30 (dt, J 8, 2 Hz, 1H), 7.05 (in, 2H), 6.85 1H), 6.73 J =9 Hz, 1H), 6.70 J 9 Hz, 1H) 6.53 1H) 6.34 J =9 Hz, 1H), 4.15 J 6 Hz, 2H), 4.04 J 6 HZ, 2H), 3.95 1H), 3.88 (in, 1H), 3.75 J 9 Hz, 1H), 3.49 (m 2H), 2.60 J 8 Hz, 2H), 2.45 J 7 Hz, 2H), 2.15 (in, 3H), 1.90 (im, 1H), 1.48 (hextet, J 8 Hz, 2H), 1.06 (t, J =7 Hz, 3H), 0.83 J 7 Hz, 3H); MS ES m/z 519 (p -1 Na IR (CHCl 3 cm 2964, 1783, 1604, 1461.
Anal. Calcd for C 31
H
35 NaO 7 .0.5 H 2 0: C, 67.50; H, 6.58.
Found: C, 67.76; H, 6.68.
Example 16 Preparation of [3-(2-Ethyl-5-hydroxy-4-pyrrolidin-2-y1phenoxy)propoxcy]-2-propyl-phenoxy)benzoic acid hydrochloride hydrate.
WO 01/34580 PCT/USOO/30942 -139- 0 Br S COOMe
N
4\ COOMe A. Preparation of 2-(2-benzyloxy-5-ethyl-4-(3-[3-(2methoxycarbonylphenoxy) -2propylphenoxylpropoxy}phenyl)pyrrole-l-carboxylic acid tertbutyl ester.
A mixture of 2-{3-[3-(5-benzyloxv-4-bromo-2ethylphenoxy)propoxy]-2-propylphenoxy}-benzoic acid methyl ester (3.00 g, 4.73 mmol), N-boc pyrrole-2-boronic acid (1.99 g, 9.43 mmol), tetrakis(triphenylphosphine)palladium(0) (0.54 g, 0.47 mmol), and 2 M aqueous sodium carbonate solution (25 mL) in tetrahydrofuran (60 mL) was heated at reflux for 40 h. The mixture was cooled to room temperature, diluted with water, and extracted with ethyl acetate. The organic layer was separated, washed once with water, once with saturated sodium chloride solution, dried (sodium sulfate), filtered, and concentrated in vacuo. Chromatography (silica gel, ethyl acetate/90% hexane) of the residue provided 2.6 g of the title compound as a solid. H NMR (CDC1 3 7.88 (dd, J 8, 2 Hz, 1H), 7.15-7.40 7H), 7.08 3H), 6.82 J 9 Hz, 1H), 6.68 J 9 Hz, 1H), 6.52 (s, 1H), 6.44 J 9 Hz, 1H), 6.23 J 4 Hz, 1H), 6.12 1H), 4.95 2H), 4.20 J 6 Hz, 2H); 4.15 J WO 01/34580 PCT/US00/30942 -140- 6 Hz, 2H), 3.84 3H), 2.66 J 8 Hz, 2H), 2.60 J 7 Hz, 2H), 2.30 (quintet, J 6 Hz, 2H), 1.57 (hextet, J 8 Hz, 2H), 1.28 9H), 1.18 J 7 Hz, 3H), 0.93 J 7 Hz, 3H); TOS MS ES exact mass calculated for
C
44
H
53
N
2 0 8 (p NH 4 m/z 737.3802. Found: 737.3804; -1 T (rl c 2£4. 173C, 1461.
Anal. Calcd for C 44
H
4 9 N0 8 C, 73.41; H, 6.86; N, 1.94.
Found: C, 73.76; H, 6.76; N, 2.04.
COOMe N KN COOMe 0 0" O0 COOMe B. Preparation of 2-(5-ethyl-2-hydroxy-4-{3-[3-(2methoxycarbonylphenoxy) -2-propylphenoxy] propoxy})henyl) pyrrolidine-l-carboxylic acid tert-butyl ester.
A solution of 2-(2-benzyloxy-5-ethyl-4-{3-[3-(2methoxycarbonylphenoxy)-2propylphenoxy]propoxy}phenyl)pyrrole-l-carboxylic acid tertbutyl ester (0.98 g, 1.4 mmol) in ethyl acetate (40 mL) was treated with 10% palladium-on-carbon (0.98 g) and hydrogenated at 45 psi and 45 OC for 25 h, at room temperature for 20 h, then at 45 oC for 19 h. The mixture
TM
was cooled to room temperature, filtered through Celite WO 01/34580 PCT/USOO/30942 -141and the filtrate concentrated in vacuo to provide 0.76 g 1 of the title compound as a colorless oil. H NMR (CDC1 3 8 7.87 (dd, J 8, 2 Hz, 1H), 7.37 (dt, J 8, 2 Hz, 1H), 7.10 J 9 Hz, 1H), 7.04 J 9 Hz, 1H), 6.91 1H), 6.81 J 9 Hz, 1H), 6.67 J 9 Hz, 1H), A 47 1T 6.44 J 9 Hz. 1H). 5.09 1H), 4.18 (d, J 6 Hz, 2H), 4.14 J 6 Hz, 2H), 3.84 3H), 3.45 2H), 2.64 J 8 Hz, 2H), 2.54 3H), 2.25 2.06 1H), 1.54 (hextet, J 8 Hz, 2H), 1.43 9H), 1.15 J 7 Hz, 3H), 0.90 J 7 Hz, 3H).
H
O 0 0 0 COOMe
H
N I
SCOOU
C. Preparation of 2-(4-(3-[3-(2-carboxyphenoxy)-2propylphenoxy propoxy) -5-ethyl-2-hydroxyphenyl)pyrrolidine- 1-carboxylic acid tert-butyl ester lithium salt hydrate.
A solution of 2-(5-ethyl-2-hydroxy-4-{3-[3-(2methoxycarbonylphenoxy)-2propylphenoxy]propoxy}phenyl)pyrrolidine-1-carboxylic acid tert-butyl ester (0.114 g, 0.18 mmol) in a 1:1 mixture of methanol/tetrahydrofuran (4 mL) was treated with solution of 1 M lithium hydroxide (4 mL) at room temperature for 18 h.
The mixture was concentrated in vacuo and the residue WO 01/34580 PCT/US00/30942 -142dissolved in water. The resulting mixure was extracted with ethyl acetate. The organic extract was dried (sodium sulfate), filtered, and concentrated in vacuo. The residue was diluted with diethyl ether, concentrated in vacuo, and dried to provide 90 mg of the title compound. MS ES -1 m/z 620 (p 1 Li IR (KBr, cm 2964, 1672, 1603, 1416.
Anal. Calcd for C 36
H
44
NO
8 Li H 2 0: C, 67.17; H, 7.20; N, 2.18. Found: C, 66.72; H, 6.99; N, 2.27.
H
COOU
H
N I
COOH
D. Preparation of 2-(3-[3-(2-ethyl-5-hydroxy-4-pyrrolidin- 2-yl-phenoxy)propoxyl-2-propylphenoxy}benzoic acid hydrochloride hydrate.
Into a solution of 2-(4-{3-[3-(2-carboxyphenoxy)-2propylphenoxy]propoxy}-5-ethyl-2-hydroxyphenyl)pyrrolidine- 1-carboxylic acid tert-butyl ester lithium salt hydrate (0.100 g, 0.16 mmol) in anhydrous diethyl ether (5 mL) was bubbled gaseous HC1. The resulting mixture was allowed to stir for 1 h. The mixture was concentrated in vacuo.
Chromatography (SCX cation exchange resin, 1:1 tetrahydrofuran/methanol to dilute ammonia/methanol) of the WO 01/34580 WO 0134580PCT[USOOI30942 -143residue provided a tan solid. This material was dissolved in ether and treated with gaseous HCl. This mixture was concentrated in vacuo to provide 48 mg of the title compound. H NMR (DMSO-d 6 8 12.80 (bs, 1H), 10. 12 1H) 9.34 (bs, 1H), 8.36 (bs, 1H), 7.79 (dd, J 9, 2 Hz, 1H), 7.47 (dt, J 8, 2 Hz, 1H), 7.17 J 8 Hz, 1H), 7.12 (d, J 9 Hz, 1H), 7.07 1H), 6.80 J 9 Hz, lH), 6.78 J =9 Hz, 111), 6.58 1H), 6.35 J 9 Hz, 1H), 4.56 4.20 J 6 Hz, 2H); 4.11 J =6 Hz, 2H), 3.25 (in, 2H), 2.50 (mn, 5H), 1.90-2.60 (in, 5H), 1.44 (hextet, J 8 Hz, 2H), 1.08 J 7 Hz, 3H), 0.82 J= 7 Hz, 3H); TOS MS ES exact mass calculated for C 31
H
38 N0 6 (p mfz 520.2699. Found: 520.2672.
Example 17 Preparation of 2- (2-Ethvl-5-hvdxoxy-4-thiophen-3-ylphenoxy)propoxy] -2-propyl-phenoxy)benzoic acid hydrate.
Br Q 0' Known compound: Sawyer et al., J. Med. Chem. 1995, 38, 4411.
A. Preparation of 3- [2-benzyloxy-4- (3-chioropropoxy) ethyiphenyllthiophene. A mixture of 2-(3-chloropropoxy)ethylbenzene (1.90 g, 5.30 mrnol), 3thiopheneboronic acid (2.00 g, 15.9 minol), I~r~~r~~phsnh1~)m11aiiu(0)(312 ma: 0.270 minol), 2 M aqueous sodium carbonate solution (4 mL), and n- WO 01/34580 WO 0134580PCTIUSOOI3O942 -144propanol (4 mL) in toluene (16 mL) was refluxed for 4 h.
The mixture was cooled to room temperature, diluted with diethyl ether, washed once with water and once with, saturated sodium chloride solution. The organic layer was dried (magnesium sulfate), filtered, and concentrated in vacuo. Chromatography (silica gel, 5% ethyl hexane) of thp rp~qjteiiip nrtri r~at 1 A IQflN -4-l-1 product as a white solid: mp 65-67 OC. H NNR (CDC1 3 7.58 J 2.8 Hz, 1H), 7.49 J 5.2 Hz, 1H), 7.45- 7.30 (in, 7H), 6.62 1H), 5.13 2H), 4.14 J 5.8 Hz, 2H), 3.81 J 6.3 HZ, 2H), 2.66 J =7.5 Hz, 2H), 2.29 (quintet, J 6.0 Hz, 2H), 1.24 J 7.5 Hz, 3H); MS -1 FD m/e 386 IR (CHC1 3 cm 2969, 1613, 1501, 1138.
Anal. Calcd for C 22
H
23 0 2 C1S: C, 68.29; H, 5.99. Found: C, 68.53; H, 6.00.
S 0 HO
CN
Known compound: Sawyer et al..
J. Mod. Chem. 1995, 38, 4411.
CN
B. Preparation of 2- C2-propyl-3- C3-[5-(benzyloxy)-2-ethyl- 4- (thiophen-3-yl )phenoxyj propoxy] phenoxY] benzonitrile.
A mixture of 4- (benzyloxy) (3 -chloropropoxy) (thiophen- 3-yl)ethylbenzene (1.25 g, 3.23 inmol), 3-(2-cyanophenoxy)-2- WO 01/34580 WO 0134580PCTIUSOO/30942 -145propyiphenol (0.82 g, 3.2 nunol), potassium iodide (0.21 g, 1.3 mmcl), potassium carbonate (1.12 g, 8.08 mmol), and methyl sulfoxide (2 mL) in 2-butanone (10 mL) was ref luxed for 60 h. The mixture was cooled to room temperature, diluted with ether, and washed with water. The organic layer was dried (magnesium sulfate), filtered, and hexane) of the residue provided 1.31 g of the title product as a colorless oil. 1H NMR (CDCl 3 8 7.66 J =7.8 Hz, 1H), 7.57 J 2.9 Hz, 1H), 7.48 J 5.2 Hz, 1H), 7.45-7.25 (in, 8H), 7.20 J 8.2 Hz, 1H), 7.10 J 8.1 Hz, 1H), 6.82 J 8.3 Hz, 1H), 6.77 (d, J 8.6 Hz, 1H), 6.64 1H), 6.63 J 6.4 Hz, 1H), 5.11 2H), 4.26 J 6.0 Hz, 2H), 4.22 J 6.0 Hz, 2H), 2.65 (in, 4H), 2.36 (quintet, J =5.9 Hz, 2H), 1.58 (hextet, J 7.5 Hz, 2H), 1.24 J =7.5 Hz, 3H), 0.95 (t, J=7.3 Hz, 3H); MS FD m/e 603 IR (CHCl 3 cm 2967, 2250, 1613, 1501. Anal. Calcd for C 3 8
H
37 N0 4 S: C, 75.59; H, 6.18; N, 2.32. Found: C, 74.65; H, 6.21; N, 2.57.
C. Preparation of 2- [2-propyl-3- [2-ethyl-5-hydroxcy-4- (thiophen- 3-yl )phenoxy] propoxyl phenoxyl benzonitrile.
WO 01/34580 PCT/USOO/30942 -146- 0OON
CN
CN
To a solution of 2-[2-propyl-3-[3-(5-(benzyloxy)-2-ethyl-4- (thiophen-3-yl)phenoxy]propoxy]phenoxy]benzonitrile (900 mg, 1.49 mmol) in methylene chloride (25 mL) cooled to -78 °C was added 1 M boron tribromide solution in methylene chloride (2.99 mL, 2.99 mmol) over 2 min. The resulting deep violet solution was stirred for 30 min and allowed to warm to room temperature. The mixture was diluted with water and shaken. The organic layer was separated, dried (magnesium sulfate), filtered, and concentrated in vacuo.
Chromatography (silica gel, 25% ethyl acetate, 75% hexane) provided 400 mg of the title product as a colorless oil. H NMR (CDC1 3 8 7.84 J 4.8 Hz, 1H), 7.71 J 4.9 Hz, 1H), 7.66 J 7.7 Hz, 1H), 7.62 IH), 7.42 J 7.1 Hz, 1H), 7.27 J 6.6 Hz, 1H), 7.20 1H), 7.08 J 6.9 Hz, 1H), 6.85 1H), 6.89 J 8.1 Hz, 1H), 6.74 J 8.5 Hz, 1H), 6.60 J 7.6 Hz, 1H), 4.71 1H, 4.26 J 6.0 Hz, 4H), 2.72 J 7.4 dHz, 2H), 2.59 J 7.3 Hz, 2H), 2.39 (quintet, J 6.1 Hz, 2H), 1.54 (hextet, J 7.7 Hz, 2H), 1.25 J Hz, 3H), 0.91 J 7.4 Hz, 3H).
WO 01/34580 PCT/US0O/30942 -147- D. Preparation of 2-[2-propyl-3-[3-[2-ethyl-5-hydroxy-4- (thiophen-3-yl) phenoxy]propoxylphenoxy]benzoic acid hydrate.
S
OH
S 0 CN
S
1
OH
COOH
A solution of 2-[2-propyl-3-[3-[2-ethyl-5-hydroxy-4- (thiophen-3-yl)phenoxy]propoxy]phenoxy]benzonitrile (400 mg, 0.780 mmol) in 2:1 methanol/water (6 mL) was treated with 12.5 M aqueous sodium hydrxide (4.0 mL) at reflux for 3 h.
The mixture was cooled to room temperature, diluted with water, and extracted once with diethyl ether. The aqueous layer was acidified with concentrated hydrochloric acid and extracted twice with methylene chloride. The combined methylene chloride layers were dried (magnesium sulfate), filtered, and concentrated in vacuo to provide a tan solid: mp 90-95 oC (dec). H NMR (CDC13) 8 8.24 J 7.8 Hz, 1H), 7.47 J 5.0 Hz, 1H), 7.44 J 8.6 Hz, 1H), 7.36 J 3 Hz, 1H), 7.24 J 4.9 Hz, 1H), 7.19 (m, 2H), 7.09 1H), 6.84 J 8.0 Hz, 1H), 6.73 J 8.3 Hz, 1H), 6.64 J 8.0 Hz, 1H), 6.55 1H), 5.38 (bs, 1H, 4.26 J 6.2 Hz, 2H), 4.21 J 7.1 Hz, 2H), 2.60 4H), 2.36 (quintet, J 5.8 Hz, 2H), 1.51 (hextet, J 7.1 Hz, 2H), 1.19 J 7.5 Hz, 3H), 0.90 (t, -1 J 7.4 Hz, 3H); MS FD m/e 532 IR (KBr, cm 3200 WO 01/34580 PCT/US00/30942 -148- 2961, 1697, 1457, 1110. Anal. Calcd for C 31
H
32 0 6 S
H
2 0: C, 67.62; H, 6.22. Found: C, 67.34; H, 5.87.
VI. Pharmaceutical Compositions of the Invention Preferably compounds of the invention (per Formulae I or II) or pharmaceutical formulations containina these compounds are in unit dosage form for administration to a mammal. The unit dosage form can be a capsule, an IV bag, a tablet, or a vial. The quantity of Active Ingredient in a unit dose of composition is a therapeutically effective amount and may be varied according to the particular treatment involved. It may be appreciated that it may be necessary to make routine variations to the dosage depending on the age and condition of the patient. The dosage will also depend on the route of administration.
The compound can be administered by a variety of routes including oral, aerosol, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal.
Pharmaceutical formulations of the invention are prepared by combining mixing) a therapeutically effective amount of the compounds of the invention compounds of Formula I, II) together with a pharmaceutically acceptable carrier or diluent therefor.
The present pharmaceutical formulations are prepared by known procedures using well known and readily available ingredients.
In making the compositions of the present invention, the Active Ingredient will usually be admixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper or other container. When the carrier serves as a diluent, it may be a solid, lyophiized solid or pasce, semi-solid, or liquid material which acts as a vehicle, or WO 01/34580 PCT/US00/30942 -149can be in the form of tablets, pills, powders, lozenges, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), or ointment, containing, for example, up to 10% by weight of the active compound. The compounds of the present invention are preferably formulated prior to administration.
For the nh'rmrlacPi11t-ir;;1 f omii1t-irn~ nv in 11h carrier known in the art can be used. In such a formulation, the carrier may be a solid, liquid, or mixture of a solid and a liquid. For example, for intravenous injection the compounds of the invention may be dissolved in at a concentration of about 0.05 to about 5.0 mg/ml in a 4% Na citrate aqueous solution.
Solid form formulations include powders, tablets and capsules. A solid carrier can be one or more substances which may also act as flavoring agents, lubricants, solubilisers, suspending agents, binders, tablet disintegrating agents and encapsulating material.
Tablets for oral administration may contain suitable excipients such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, together with disintegrating agents, such as maize, starch, or alginic acid, and/or binding agents, for example, gelatin or acacia, and lubricating agents such as magnesium stearate, stearic acid, or talc.
In powders the carrier is a finely divided solid which is in admixture with the finely divided Active Ingredient.
In tablets the Active Ingredient is mixed with a carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
Advantageously, compositions containing the compound of Formula may be provided in dosage unit form, preferably each dosage unit containing trom about 5 to about 500 mg (from about 5 to 50 mg in the case of parenteral or WO 01/34580 PCT/US00/30942 -150inhalation administration, and from about 25 to 500 mg in the case of oral or rectal administration. Dosages from about 0.5 to about 300 mg/kg per day, preferably 0.5 to mg/kg, of Active Ingredient may be administered although it will, of course, readily be understood that the amount of the compound or compounds of Formula I actually to be ad: r crsred. ill hT e t-rmil nri by a nhvici.an. in the liqht of all the relevant circumstances.
Powders and tablets preferably contain from about 1 to about 99 weight percent of the Active Ingredient which is the novel compound of this invention. Suitable solid carriers are magnesium carbonate, magnesium stearate, talc, sugar lactose, pectin, dextrin, starch, gelatin, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, low melting waxes, and cocoa butter.
Sterile liquid form formulations include suspensions, emulsions, syrups and elixirs.
The Active Ingredient can be dissolved or suspended in a pharmaceutically acceptable carrier, such as sterile water, sterile organic solvent or a mixture of both. By "pharmaceutically acceptable" it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
The Active Ingredient can also be dissolved in a suitable organic solvent, for instance aqueous propylene glycol. Other compositions can be made by dispersing the finely divided Active Ingredient in aqueous starch or sodium carboxymethyl cellulose solution or in a suitable oil.
The following pharmaceutical formulations 1 to 8 are illustrative only and are not intended to limit the scope of the invention in any way. "Active Ingredient", refers to a compound according to Formula or (II) or a WO 01/34580 PCT/US00/30942 -151pharmaceutically acceptable salt, solvate, or prodrug thereof.
Formulation 1 Hard gelatin capsules are prepared using the following ingredients: Active Ingredient Starch, dried Magnesium stearate Total Quantity (mg/capsule) 250 200 460 mg Formulation 2 A tablet is prepared using the ingredients below: Active Ingredient Cellulose, microcrystalline Silicon dioxide, fumed Stearic acid Total Quantity (mg/tablet) 250 400 665 mg The components are blended and compressed to form tablets each weighing 665 mg Formulation 3 An aerosol solution is prepared containing the following components: Weight Active Ingredient 0.25 WO 01/34580 PCT/US00/30942 -152- Ethanol Propellant 22 (Chlorodifluoromethane) Total 25.75 74.00 100.00 The Active Ingredient is mixed with ethanol and the mixture added to a portion of the propellant 22, cooled to -30 0 C and then fed to a stainless steel container and diluted with the remainder of the propellant. The valve units are then fitted to the container.
Formulation 4 Tablets, each containing 60 mg of Active Ingredient, are made as follows: Active Ingredient Starch Microcrystalline cellulose Polyvinylpyrrolidone (as 10% solution in water) Sodium carboxymethyl starch Magnesium stearate Talc Total 60 mg 45 mg 35 mg 4 mg 4.5 mg 0.5 mg 1 mg 150 mg The Active Ingredient, starch and cellulose are passed through a No. 45 mesh U.S. sieve (355 pm) and mixed thoroughly. The aqueous solution containing polyvinylpyrrolidone is mixed with the resultant powder, and the mixture then is passed through a No. 14 mesh U.S. sieve (1.4mm). The granules so produced are dried at 50 0 C and passed through a No. 18 mesh U.S. sieve (1.00mm). The sodium carboxymethyl starch, magnesium stearate and talc, previously passed through a No. 60 mesh U.S. sieve (250 pm), are then added to the granules which, after mixing, are WO 01/34580 PCT/US00/30942 -153compressed on a tablet machine to yield tablets each weighing 150 mg.
Formulation Capsules, each containing 80 mg of Active Ingredient, are made as follows: Active Ingredient 80 mg Starch 59 mg Microcrystalline cellulose 59 mg Magnesium stearate 2 mg Total 200 mg The Active Ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 45 U.S. sieve (355pm), and filled into hard gelatin capsules in 200 mg quantities.
Formulation 6 Suppositories, each containing 225 mg of Active Ingredient, are made as follows: Active Ingredient 225 mg Saturated fatty acid glycerides 2,000 mg Total 2,225 mg The Active Ingredient is passed through a No. 60 U.S.
sieve (250 pm)and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2g capacity and allowed to cool.
Formulation 7 WO 01/34580 PCT/US00/30942 -154- Suspensions, each containing 50 mg of Active Ingredient per ml dose, are made as follows: Active Ingredient 50 mg Sodium carboxymethyl cellulose 50 mg Syrup 1.25 ml benzoic acid solution 0.10 mlt Flavor q.v.
Color q.v.
Purified water to total 5 ml The Active Ingredient is passed through a No. 45 mesh U.S.
sieve (355 pm) and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor and color are diluted with a portion of the water and added, with stirring. Sufficient water is then added to produce the required volume.
Formulation 8 An intravenous formulation may be prepared as follows: Active Ingredient 100 mg Isotonic saline 1,000 ml The solution of the above materials generally is administered intravenously to a subject at a rate of 1 ml per minute.
All of the products of the Examples described below as well as intermediates used in the following procedures showed satisfactory nmr and ir spectra. They also had the correct mass spectral values.
WO 01/34580 PCT/USOO/30942 -155- VII. Method of Using the Compounds of the Invention This invention is a method for preventing or treating
LTB
4 induced inflammation in a mammal by contacting the
LTB
4 in a mammal with an LTB 4 antagonizing amount of the heterocyclic substituted diphenyl compounds of the invention (as per formula i or ii) or a Sd±L, uiva1tL uL prodrug of said compounds.
Another aspect of this invention is a method for preventing or treating Inflammatory Diseases such as inflammatory bowel disease, septic shock, adult respiratory distress syndrome, panceatitis, trauma, bronchial asthma, allergic rhinitis, rheumatoid arthritis, osteoarthritis, and related diseases which comprises administering to a mammal (including a human) a therapeutically effective dose of heterocyclic substituted ulphenyl i UL of the invention pe.r Ll.a.. I.
II) or a salt, solvate or prodrug of said compounds.
The specific dose of a compound administered according to this invention to obtain therapeutic or prophylactic effects will, of course, be determined by the particular circumstances surrounding the case, including, for example, the compound administered, the route of administration and the condition being treated. Typical daily doses will contain a non-toxic dosage level of the compound of formulae When route of administration is parenteral the dose is about 0.1 to about 100 milligrams per day. Intravenous administration can include a continuous drip. When the route is oral the dose is about 1 to about 1000 milligrams per day. Preferred dosages are from about 0.5 to about 300 mg/kg per day, most preferably 0.5 to 20 mg/kg, of Active Ingredient may be administered although it will, of course, readily be understood that the amount of the compound or compounds of Formula I actually to be administered will be WO 01/34580 PCT/US00/30942 -156determined by a physician, in the light of all the relevant circumstances.
VIII. Assay Method The following Assay method was used to evaluate the effects of 3 compounds for LTB 4 -mediated CD11b upregulation on human neucrophils: Note: The Assay procedure described herein was modeled after a previously published method(viz., Prostaglandins, Leukot, Essent. Fatty Acids. 46:265-270. 1992, Biochem.
Pharmacol. 49:1683-1690. 1995), the disclosure of which is incorporated herein by reference.
The compound C (within the scope of the invention) was evaluated for LTB 4 antagonist efficacy. Compounds A and B were control compounds. Compound A is a leukotriene B 4 antagonist known to be effective, but belonging to a different class of compounds than rcprcsented by formulae I or II, supra. Comparison compound B is structurally similar to the compounds of the invention, but lacks certain essential functional groups necessary for an effective LTB 4 antagonist.
Approximately 1-2 mg of each compound was weighed and diluted to 1 mM in neat dimethyl sulphoxide (DMSO). These stocks were then diluted (using "doubling" dilutions) in assay buffer.
The assay buffer used throughout the studies consisted of Hanks Balanced Salts Solution (HBSS) with added bovine serum albumin, low endotoxin (ICN Biomedicals Catalog 16-980-49). After dissolving the BSA in the HBSS, the buffer was membrane-filtered (0.2g) before use.
Human blood was drawn into 3 x 10 ml EDTA-K 3 Vacutainer tubes, which were pooled and mixed in a 50 ml, blue cap polypropylene tube. Three ml portions of Mono-Poly Resolving medium (MPRM; ICN #16-980-49) were dispensed into WO 01/34580 PCT/USOO/30942 -157- 4 separate 13 x 100 glass disposable tubes. An additional 0.3 ml of PBS (phosphate buffered saline) was added to each tube and mixed with the MPRM by vigorous vortexing. Exactly ml of the blood was carefully layered on top of the four MPRM-water mixtures. The tubes were gradually accelerated to 400 x g and spun at this speed for 30 min at room u.illjfc J a sl4. C A. 3 both the plasma and top cell (mononuclear) layers were removed and discarded. The second layer of cells was carefully collected, pooled and washed with assay buffer.
The collected neutrophil cell preparation was then spun at 400 x g for 5 min and re-washed once again. The cells were resuspended in assay buffer and counted using a Cell-Dyn 1600 cell counter (Abbott Diagnostics They were then resuspended in buffer at 9 x 106 cells/ml and held briefly for addition in a later step of the assay.
LTB4, (Biomol ETOH stock 148.5 was diluted to a 3.9 MM stock in assay buffer by dilution of 10 il ETOH stock 371 4l assay buffer, mixed well and further diluted 1:100 (100 Ml 9.9 ml buffer) to make a use stock of 39 nM in buffer for later use. The final concentration of LTB 4 (3 nM) was determined after several experimental runs.
Exactly 10 gl of each putative compound/dilution and Ml of anti-CDllb-FITC (FITC Fluorescein Isothiocyanate; Biosource Intl., AHS1148) was carefully added to the bottom of 12 x 75 mm polypropylene tubes (Falcon 2063) as determined by the experimental design. Following this, 100 Ml of the human neutrophil preparation (9E6/ml) was added and mixed well by vortexing. The compound/cell mixtures were incubated together for 15 minutes at room temperature.
Following this incubation, 10 Ml of diluted LTB 4 stock was added (to make 3 nM final LTB 4 concentration), mixed by vortexing and incubated in a 37°C shaking water bath for min. Following this the tubes were immediately placed on WO 01/34580 PCT/US00/30942 -158ice for 10 minutes. Following this 1 ml of diluted BD FACS Lyse (Becton Dickinson Fluorescense Activated Cell Sorting Lyse) was added to the tubes and vortexed. 10 minutes later the tubes were spun at 400 x g at room temperature. After centrifugation, the tubes were aspirated and re-suspended in ml of 1% paraformaldehyde solution.
mT h 1 \cc t.he ana- yzcd f cr* f recenc intensity (linear scale) using an EPICS XL flow cytometer and the "Mo-1 Isolated Neutrophil" protocol.
The mean fluorescence intensity (MFI) for each sample was computed using WinList software and expressed as percentage of maximum MFI.Microsoft Excel and further graphed and analyzed using linear regression.
WO 01/34580 WO 0134580PCT[USOO/30942 -159- Table 1 Assay Results Compounds of the Invention Example No. t1 bC~ 480 (nM 2 5880 3 3ij9 4 74;117 175;223 6 260 7 2020;3790 8 >50000 9 23;20 14;4.4;8.3 11 620;2560;1010 12 10000;5700 13 39;54 14 31;30 27 16 1080;'837 17 11;5.6;8 *note -semicolons separate individual assay determinations Table 2 Assay Results for Comparison Compounds average of 3 tests WO 01/34580 PCT/US00/30942 -160- Compound A a known LTB 4 antagonist (see, Example 66 of U.S. Patent No. 5,462,954) which is not heterocycle substituted and is not an aspect of this invention: Compound B a control compound related to Compound A and not an aspect of this invention, represented by the formula:

Claims (36)

1. A compound represented by the formula (I) (I) wherein: X is selected from the group consisting of, a five membered substituted or unsubstituted heterocyclic radical containing from 1 to 4 hetero atoms independently selected from sulfur, nitrogen or oxygen; and (ii) a fused bicyclic radical wherein a carbocyclic group is fused to two adjacent carbon atoms of the five membered heterocyclic radical, Y 1 is a bond or divalent linking group containing 1 to 9 atoms; Y 2 and Y 3 are divalent linking groups independently selected from -CH 2 or Z is an Acidic Group; WO 01/34580 WO 0134580PCTUSOO/30942 -162- Ri is C 1 -Cl 0 alkyl, aryl, C 3 -C 8 cycloalkyl, C 2 -C 1 0 alkenyl, C 2 -C 10 alkynyl, C 6 -C 20 aralkyl, C 6 -C 20 alkaryl, C 1 -C 10 haloalkyl, C 6 -C 2 0 aryloxy, or C 1 -C 10 alkoxy; R2 is hydrogen, halogen, Cl-Cj 0 haloalkyl, C 1 -C 10 alkoxy, Cj-Cl 0 alkyl, C 3 -C 8 cycloalkyl, Acidic Group, or (CH 2 l-7-(Acidic Group); R3 is hydrogen, halogen, Cl-Cl 0 alkyl, aryl, Cl-C 1 0 haloalkyl, Cj-Cl 0 alkoxy, 0 6 -C 2 0 aryloxy, or 3C cycloalkyl; R4 is Cl-C 4 alkyl, C 3 -C 4 cycloalkyl, -(CH 2 1 7 -(C 3 -C 4 cycloalkyl), C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, benzyl, or aryl; and n is 0, 1, 2, 3, 4, 5, or 6; or a pharmaceutically acceptable salt, solvate, or prodrug derivative thereof.
2. The compound of claim 1 wherein X is a heterocyclic radical selected from the group consisting of substituents represented by the following formulae; R1 Rio 1\ R 11 4 0 S R 11 0N WO 01/34580 WO 0134580PCT/USOO/30942 -163- NI R ll N R I N-N sI -Rl N Rll N RI N-N II KzN Rl 1 Ru1 NN 0 0 IN 0 S) N H WO 01/34580 PCT/US00/30942 -164- and H11 where R10 is a radical selected from hydrogen or C 1 -C 4 alkyl; and R11 is a radical selected from hydrogen, halo, C 1 -C 10 alkyl, C 1 -C 10 haloalkyl, C 1 -C 10 alkoxy, aryl, or C 6 -C 20 aryloxy.
3. The compound of claim 2 wherein the heterocyclic radical is selected from the group consisting of substituents represented by the formulae; HN Ox ,and SC-
4. The compound of claim 1 or 2 or 3 wherein Y 1 is a divalent linking group selected from the following formulae: WO 01/34580 WO 0134580PCTfUSOO/30942 -165- -0 -C H 2 -N R13 -S 0 -C -C C H 2 H 2 H, H 2 -N C R13 0 Ii H2 0 -C C II H 2 0 where R13 is hydrogen, methyl, or ethyl. WO 01/34580 WO 0134580PCT/USOO/30942 -166- The compound of claim 4 wherein Yl is the divalent linking group; -0
6. The compound of claim 1 or 2 or 3 wherein the acidic group Z is selected from the following: -C N- S 12 0 tetrazolyl, -SO3H, -POH I OH IiOH N s WO 01/34580 PCT/US00/30942 -167- where R12 is C 1 -C 10 alkyl, aryl, C 6 -C 20 alkaryl, or C6-C20 aralkyl.
7. The compound of claim 6 wherein the acidic group Z is selected from -5-tetrazolyl, N-acyl sulfonamide, -303F, J catL Cx-.
8. The compound of claim 7 wherein the acidic group Z is carboxyl.
9. The compound of claim 1 or 2 or 3 wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, or 2-propenyl. The compound of claim 1 or 2 or 3 wherein R2 and R3 are independently selected from hydrogen or methyl; ethyl, methoxy, ethoxy, halo, or -CF 3
11. The compound of claim 10 wherein R2 and R3 are hydrogen.
12. The compound of claim 1 ethyl, propyl, or isopropyl.
13. The compound of claim 1 numerical value of subscript n is
14. The compound of claim 1 Y 3 are both The compound of claim 1 sodium salt. or 2 or 3 wherein R4 is 2 or 3 wherein the or 2 or 3 wherein Y 2 and or 2 or 3 in the form of a 168
16. The compound of claim 1 or 2 or 3 in the formn of a prodrug which is an ester of the Acidic Group; provided that the Acidic Group is a carboxyl.
17. The compound of claim 16 wherein the Acidic Group is carboxyl and the prodrug is selected from methyl ester, ethyl ester, propyl ester, isopropyl ester, n-butyl ester, isobutyl ester, tert-butyl ester, morpholinoethyl ester, or N,N-diethylglycolamido ester. 1 R The compound of claim I wherein the RI, R2, R3 and R4 groups for substitution in formula are selected from the following variables coded ROI thru R16 R variables RI group R2 group R3 group R4 group Combination Code choice choice choice choice ROl RI R2 R3 R4 R02 RI R2 R3 PG1-R4 R03 RI R2 PG1I-R3 R4 R04 R I R2 PG1I-R3 PG1-R4 Ri1 PG1I-R2 R3 R4 R06 RI PG1I-R2 R3 PU I -R4 R07 R I PG1-R2 PG1-R3 R4 R08 R I PGI-R2 PGI-R3 PG1-R4 R09 PG1-RI R2 R3 R4 RIO PGI-RI R2 R3 PGI-R4 RII PGI-RI R2 PG1I-R3 R4 R12 PGI-R1 R2 PG1-R3 PG1-R4 R13 PGI-R1 PG1-R2 R3 R4 R14 PGI-R1 PG I-R2 R3 PG1-R4 R15 PGI-R1 PGI-R2 PGI-R3 R4 R16 PG1-R1 PGI-R2 PG1I-R3 PG1I-R4 R: \LBVV ]03480spec idocnjc WO 01/34580 PCTIUSOOI30942 -169- and; the Yl, Y2, and Y3 groups for substitution in formula (I) are selected from the following variables coded Y01 thru Y27: WO 01/34580 WO 0134580PCTIUSOOI30942 -170- Y variables Yl group Y2 group Y3 group combination choice choice choice code Y0l Yl Y2 Y3 Y02 Y1 Y2 PG1-Y3 Nr1 A' 1 %7 Y04 Y1 PG1-Y2 Y3 Yl PG2-Y2 Y3 Y06 Y1 PG1-Y2 PGl-Y3 Y07 Y1 PGl-Y2 PG2-Y3 YO8 Yl PG2-Y2 PGl-Y3 Y09 Yl PG2-Y2 PG2-Y3 PGl-Y1 Y2 Y3 Yll PGl-Yl Y2 PGl-Y3 Y12 PGl-Yl Y2 PG2-Y3 Y13 LP.i- yi PGi-Y2 Y3 Y14 PGl-Yl PGl-Y2 PGl-Y3 PGl-Y1 PGl-Y2 PG2-Y3 Y16 PGl-Yl PG2-Y2 Y3 Y17 PGl-Yl PG2-Y2 PGl-Y3 Y18 PGl-Yl PG2-Y2 PG2-Y3 Y19 PG2-Y1 Y2 Y3 PG2-Yl Y2 PGl-Y3 Y21 PG2-Yl Y2 PG2-Y3 Y22 PG2-Y1 PG1-Y2 Y3 Y23 PG2-Yl PG1-Y2 PG1-Y3 Y24 PG2-Y1 PGl-Y2 PG2-Y3 PG2-Yl PG2-Y2 Y3 Y26 PG2-Yl PG2-Y2 PG1-Y3 Y27 PG2-Yl PG2-Y2 PG2-Y3 WO 01/34580 PCT/US00/30942 -171- and; the X and Z groups and the n variable for substitution in formula are selected from the following variables coded XZnOl thru XZn24: WO 01/34580 WO 0134580PCT/USOO/30942 -172- XZn variables X Z n integer combination group Group group code choice Choice choice XZnQ1 X z n XZnO2 X Z PG1-n xzflu- A I,1 XZnO4 X PG1-Z n X PG2-Z n xznO6 X P03-Z n XZnO7 X PG1-Z PGl-n XZnQ8 X PG2-Z PGl-n XZnO9 X PG3-Z PGl-n XZnlO X PG1-Z PG2-n XZnl1 X PG2-Z PG2-n XZnl2 X PG3-Z PG2-n I XZnl3 PG1-X Z n XZnl4 PGl-X Z PGl-n PG1-X Z PG2-n XZnl6 PG1-X PGl-Z n XZn17 PG1-X PG2-z n XZn1B PGl-X PG3-Z n XZnl9 PG2-X PG1-Z PGl-n XZn2O PG2-X PG2-Z PG1-n XZn21 PG2-X PG3-z PGl-n XZn22 PG2-X PG1-Z PG2-n XZn23 PG2-X PG2-Z PG2-n XZn24 PG2-X PG3-Z PG2-n WO 01/34580 WO 0134580PCTUSOO/30942 -173-
19. A compound effective as a leukotriene B4 antagonist, described by formula (II): H X2 R121 wherein; X2 is a heterocyclic radical selected from, CHF 0 or R21 is ethyl, 2-propen-l-yl, 3-propen--l-yl, n-propyl, iso-propyl, n-butyl, sec-butyl, or tert-butyl; and R22 is hydrogen, n-butyl, sec-butyl, flouro, chioro, -F or tert-butyl. Z2 is the Acidic Group selected from carboxyl, tetrazolyl, or N-sulfonamidyl; WO 01/34580 WO 0134580PCTIUS00/30942 -174- or a salt, solvate or prodrug thereof. A compound selected from the following: /N OH COOH H*HCI 4N OH N~. WO 01/34580 PCTUSOO/30942 -175- WO 01/34580 WO 0134580PCT[USOO/30942 -17 6- COOH COOH COONa COOH WO 01/34580 WO 0134580PCTIUSOO/30942 -17 7- OH 0 OH CN OH Un U COOH s OH COCH COOH WO 01/34580 WO 0134580PCT/USOO/30942 -178- <9p COOH COOH COOH WO 01/34580 WO 0134580PCT/USOO/30942 -17 9- 0 N COOH or OH S 1 N N COOH or an acid, salt, solvate or prodrug derivative thereof.
21. A compound selected from the following: COOH WO 01/34580 WO 0134580PCTUSOOI30942 -180- H 510J COOH OH COOH COOH or OH COOH or an acid, s alt, solvate or prodrug derivative thereof.
22. A compound of claim 20 or 21 wherein the acid, salt and prodrug derivatives are respectively selected from; carboxylic acid, sodium salt, and ester prodrug. WO 01/34580 PCT/US00/30942 -181-
23. A pharmaceutical composition which comprises a therapeutically effective amount of a compound according to claim 1 or 2 or 3 or 18 or 19 or 20 or 21 and a pharmaceutically acceptable carrier or diluent.
24. A method for the treatment or prevention of inriammatory viseases, which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound according to claim 1 or 2 or 3 or 18 or 19 or or 21. A method for in vivo inhibition of leukotriene B 4 in a mammal in need thereof, which comprises administering to said mammal a therapeutically effective amount of a compound according to claim 1 or 2 or 3 or 18 or 19 or 20 or 21.
26. The method of claim 25 wherein the route of administration is oral and the dose is about 1 to about 1000 milligrams per day.
27. The method of claim 25 wherein the route of administration is parenteral and the dose is about 0.1 to about 100 milligrams per day.
28. A compound of claim 1 or 2 or 3 or 18 or 19 or or 21 for use as a medicament in the treatment or prevention of Inflammatory Diseases.
29. A compound of claim 1 or 2 or 3 or 18 or 19 or or-21 for use as a medicament in the in vivo inhibition of leukotriene B 4 in a mammal in need thereof. 182 A compound of Formula as claimed in any one of claims 1 to 22 substantially as hereinbefore described with reference to any one of the Examples or Reaction Schemes.
31. A process for preparing a compound of Formula as claimed in any one of claims 1 to 22 which process is substantially as hereinbefore described with reference to any one of the Examples or Reaction Schemes.
32. A compound of formula I whenever prepared by the process of claim 31.
33. A pharmaceutical composition substantially as herein described with reference to any one of Formulation Examples 1 to 8.
34. A method for the treatment or prevention of inflammatory diseases comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 30 or 32 or a pharmaceutical composition of claim 23 or 33. A method for in vivo inhibition of leukotriene B 4 in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound of claim 30 or 32 or a pharmaceutical composition of claim 23 or 33.
36. A compound of formula I of any one of claims 1 to 22 or claim 30 or 32 when used to treat or prevent inflammatory diseases.
37. A compound of formula I of any one of claims 1 to 22 or 30 or 32 when used in the in vivo inhibition of leukotriene B 4 in a mammal in need thereof.
38. A pharmaceutical composition of claim 23 or 33 when used to treat or prevent inflammatory diseases.
39. A pharmaceutical composition of claim 23 or 33 when used in the in vivo inhibition of leukotriene B 4 in a mammal in need thereof.
40. Use of a compound of formula I of any one of claims 1 to 22 or 30 or 32 in 25 the manufacture of a medicament to treat or prevent inflammatory disease.
41. Use of a compound of formula I of any one of claims 1 to 22 or 30 or 32 for the manufacture of a medicament for the in vivo inhibition of leukotriene B 4 in a mammal.
42. The method of claim 24, 25, 34 or 35 wherein said mammal is a human.
43. The compound of claim 29 or 37 wherein said mammal is a human.
44. The pharmaceutical composition of claim 39 wherein said mammal is a human. (Ra\LIBVV3480pcci doc:njc 183 The use of claim 41 wherein said mammal is a human. Dated 19 July, 2004 Eli Lilly and Company Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON *fee *f 6e :0. 6 6 .0. [R \UBVV j348Ospci doc njc
AU17610/01A 1999-11-11 2000-11-09 Heterocycle substituted diphenyl leukotriene antagonists Ceased AU777221B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16470399P 1999-11-11 1999-11-11
US60/164703 1999-11-11
PCT/US2000/030942 WO2001034580A1 (en) 1999-11-11 2000-11-09 Heterocycle substituted diphenyl leukotriene antagonists

Publications (2)

Publication Number Publication Date
AU1761001A AU1761001A (en) 2001-06-06
AU777221B2 true AU777221B2 (en) 2004-10-07

Family

ID=22595708

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17610/01A Ceased AU777221B2 (en) 1999-11-11 2000-11-09 Heterocycle substituted diphenyl leukotriene antagonists

Country Status (8)

Country Link
EP (1) EP1263743A1 (en)
JP (1) JP2003513962A (en)
CN (1) CN1387518A (en)
AU (1) AU777221B2 (en)
BR (1) BR0015482A (en)
CA (1) CA2391230A1 (en)
MX (1) MXPA02004646A (en)
WO (1) WO2001034580A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797723B1 (en) 1999-11-11 2004-09-28 Eli Lilly And Company Heterocycle substituted diphenyl leukotriene antagonists
GB0315111D0 (en) * 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
US7964596B2 (en) * 2008-03-07 2011-06-21 Allergan, Inc. Therapeutic compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0544488A2 (en) * 1991-11-25 1993-06-02 Eli Lilly And Company Substituted phenyl phenol leukotriene antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH30449A (en) * 1991-11-25 1997-05-28 Lilly Co Eli Substituted phenyl phenol leukotriene antagonists
US5925654A (en) * 1997-03-12 1999-07-20 G.D. Searle & Co. LTA4 , hydrolase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0544488A2 (en) * 1991-11-25 1993-06-02 Eli Lilly And Company Substituted phenyl phenol leukotriene antagonists

Also Published As

Publication number Publication date
WO2001034580A1 (en) 2001-05-17
BR0015482A (en) 2002-06-25
CA2391230A1 (en) 2001-05-17
EP1263743A1 (en) 2002-12-11
MXPA02004646A (en) 2002-09-02
JP2003513962A (en) 2003-04-15
AU1761001A (en) 2001-06-06
CN1387518A (en) 2002-12-25

Similar Documents

Publication Publication Date Title
JP3137222B2 (en) Substituted N-piperidino-pyrazole-3-carboxamides
CN1331848C (en) Tricyclic steroid hormone nuclear receptor modulators
JP4964380B2 (en) Tricyclic derivative of pyrazole carboxylic acid, process for producing the same and pharmaceutical composition containing the same
KR850000240B1 (en) Method for preparing imidazo [1,2-a] pyridine
AU679053B2 (en) Indoletetralins having dopaminergic activity
CZ288527B6 (en) Benzofuran, benzothiophene, indole or indolizine derivatives process of their preparation, their use and pharmaceutical preparation in which they are comprised
IL109234A (en) Indole derivatives, their preparation and pharmaceutical compositions containing them
JPH06271571A (en) Indole, indazole and benzisoxazole compound, their preparation, and pharmaceutical compositions containing them
KR19990006912A (en) Tricyclic Pyrazole Derivatives
JPS63183576A (en) Novel imide derivative
HU211296A9 (en) Lignan analogues, methods of preparation thereof and anti-hyperlipemic agents
AU777221B2 (en) Heterocycle substituted diphenyl leukotriene antagonists
ES2292712T3 (en) BENZO DERIVATIVES (B) THIOPHEN AND PROCEDURE FOR PREPARATION.
JPH068285B2 (en) Tricyclic amine, process for producing the same and pharmaceutical composition
JPH054383B2 (en)
AU752820B2 (en) Biphenylene lactams as prostaglandin receptor ligands
US6797723B1 (en) Heterocycle substituted diphenyl leukotriene antagonists
JPS63246364A (en) Drug composition
KR100382998B1 (en) 6-methoxy-1H-benzotriazole-5-carboxamide derivatives, methods for preparing the same, and pharmaceutical compositions containing the same
AU610629B2 (en) Improvements in or relating to leukotriene antagonists
Sato et al. Synthesis and evaluation of novel fluorinated sulotroban-related sulfonamide derivatives as thromboxane A2 receptor antagonists
HU203517B (en) Process for producing leukotriene-antagonists as acids, acid derivatives and tetrazols
JP2653382B2 (en) 3-sulfonyl-3,7-diazabicyclo [3,3,1] 1nan-compound, process for producing the same, and medicament for treating gastric motor dysfunction
KR920006784B1 (en) Anti-inflammatory 1-heteroaryl-oxindole-3-carboxamide
JPH0764843B2 (en) Novel compound, method for producing the same, and pharmaceutical composition containing the same